

## Harvard Medical School Curriculum Vitae

**Date Prepared:** August 11, 2021

**Name:** David M. Weinstock

**Office Address:** Dana-Farber Cancer Institute  
450 Brookline Avenue, Dana 510B  
Boston, MA 02215

**Home Address:** 6 Moss Hill Road  
Boston, MA 02130

**Work Phone:** 617-632-4245

**Work Email:** [davidm\\_weinstock@dfci.harvard.edu](mailto:davidm_weinstock@dfci.harvard.edu)

**Work FAX:** 617-632-6380

**Place of Birth:** Washington, DC

### Education

1993	AB (Honors)	Biology	University of Chicago, Chicago, IL
1997	MD	Medicine	George Washington University School of Medicine and Health Sciences, Washington, DC
2019	MA (Honorary)	Arts	Harvard University, Cambridge, MA

### Postdoctoral Training

7/1997-6/1998	Intern	Medicine	New York Hospital-Cornell, New York, NY
6/1998-6/2000	Resident	Medicine	New York Hospital-Cornell
2/2000-6/2000	Assistant Chief Resident	Medicine	New York Hospital-Cornell
7/2000-6/2003	Fellow	Medical Oncology	Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY
7/2001-6/2004	Fellow	Infectious Diseases	MSKCC

7/2002-6/2005	Research Fellow	Molecular Biology (Maria Jasin, PhD)	Sloan Kettering Institute, MSKCC, New York, NY
7/2004-6/2005	Special Fellow	Medicine	MSKCC

### Faculty Academic Appointments

10/2005-3/2007	Instructor	Medicine	Weill-Cornell Medical College (WCMC), New York, NY
3/2007-4/2008	Assistant Professor	Medicine	WCMC
1/2008-1/2010	Instructor	Medicine	Harvard Medical School (HMS), Boston, MA
2/2010-4/2014	Assistant Professor	Medicine	HMS
5/2014-2/2019	Associate Professor	Medicine	HMS
6/2017-2/2019	Associate Professor	Pediatrics	HMS
10/2018-	Faculty	Harvard Program in Therapeutic Science	HMS
2/2019-	Professor	Medicine	HMS
2/2019-	Professor	Pediatrics	HMS

### Appointments at Hospitals/Affiliated Institutions

#### **Past**

10/2005-3/2007	Staff Physician	Medicine	MSKCC
3/2007-4/2008	Assistant Member, Level 1	Medicine	MSKCC

#### **Current**

1/2008-	Institute Physician	Medical Oncology	Dana-Farber Cancer Institute (DFCI), Boston, MA
1/2008-	Member	Medical Oncology	Dana-Farber/Harvard Cancer Center (DF/HCC) Cancer Genetics and Leukemia Programs, Boston, MA

1/2008-	Associate Physician	Medicine	Brigham and Women's Hospital (BWH), Boston, MA
2/2017-	Associate Scientific Research Staff	Medicine	Boston Children's Hospital (BCH), Boston, MA
9/2020-	Lavine Family Chair for Preventative Medicine	Medical Oncology	DFCI

### Other Professional Positions

2016-	Founder	Public Repository of Xenografts (PRoXe)	
2018-	Allen Distinguished Investigator	Paul G. Allen Institute Frontiers Group	
2018-2018-2019	Co-founder Member, Scientific Advisory Board	Travera, Inc., Cambridge, MA	One day per year
2019-	Co-founder and Member, Scientific Advisory Board	Ajax Pharmaceuticals, New York, NY	Two days per year
2019-	Member, Scientific Advisory Board	Bantam Pharmaceuticals, New York, NY	One day per year
2019	Member, Scientific Advisory Board	EDO Mundipharma, Basel, Switzerland	One day per year
2020-	Founder and Chairman of the Board	Root Diagnostics, Boston, MA	Two days per year

### Major Administrative Leadership Positions

#### Local

2006	Course Co-Director and Lecturer, Responding to Hematologic Toxicity after a Nuclear Detonation Event	MSKCC
2016-2018	Director, Leukemia and Lymphoma Xenograft Core	DFCI

2018-	Co-Leader, Leukemia Program	DF/HCC
2020-	Co-Leader, Connect:Science Virtual Seminar Series	DF/HCC and Leukemia and Lymphoma Society (LLS)
2020-	Site Medical Director	DFCI and Radiation Injury Treatment Network (RITN)

#### National

2005	Director, Healthcare Worker Education	American Red Cross, Louisiana Headquarters, Hurricane Katrina Relief
2009-2016	Medical Advisor	RITN

#### International

### [Committee Service](#)

#### Local

2006-2007	Member, Bone Marrow Transplant Quality Assurance Committee	MSKCC
2007	Member, Molecular Pathology Advisory Group	MSKCC
2009	Member, Scientific Advisory Committee, Cytogenetics Core	DF/HCC
2010-2012	External Advisor, Radiation Oncology Research Division	DFCI
2011-2014	Member, Doctoral Advisory Committee (Hubo Li)	PhD Program in Biological and Biomedical Sciences (BBS), HMS
2011, 2014, 2015	Member, Faculty Search Committee, Leukemia Program	DFCI
2011-	Member, Subcommittee on Admissions, MD-PhD Program	HMS
2012	Member, Faculty Search Committee, Division of Hematologic Neoplasia	DFCI
2012	Member, Strategic Planning Research Workshop	DFCI

2012-	Member and Chair, Faculty Advisory Committee (Alejandro Gutierrez, MD)	BCH
2013	Member, Research Computing Strategic Planning Committee	DFCI
2013	Member, Oversight Committee, Center for Biomedical Imaging in Oncology – Lurie Family Imaging Center (CBIO-LFIC)	DFCI
2013	Member, Oversight Committee, Center for Functional Cancer Epigenetics (CFCE)	DFCI
2013	Member, Oversight Committee for Faculty Development	DFCI
2013-	Member, Scholarship Oversight Committee (Yana Pikman, MD)	DFCI
2013-18	Chair, Doctoral Advisory Committee (Andrew Giacomelli)	Harvard BBS Program
2014	Member, Faculty Model Workgroup for Basic and Translational Investigators	DFCI
2014	Member, Faculty Model Workgroup for Clinical Investigators	DFCI
2014	Member, Hematologic Malignancies Diagnostics Working Group	DFCI
2014-19	Advisor and Member, Doctoral Advisory Committee (Jacob Layer)	Harvard BBS Program
2015	Member, Patient-Derived Models Planning Committee	DFCI
2015	Member, Longwood Center Vivarium Planning Committee	DFCI
2015	Member, Faculty Search Committee, Radiation Oncology	DFCI
2015-19	Member, Doctoral Advisory Committee (Caitlin Nichols)	Harvard BBS Program
2016	Member, Leukemia Sample Banking Committee	DFCI

2016	Co–Chair, Workshop on New Financing Structures for Transformative Care	Massachusetts Institute of Technology (MIT) Laboratory for Financial Engineering
2016-17	Chair, FLAIR Fellowship Grant Review Committee	DFCI
2016-	Member, K01 Advisory Committee (Shannon Elf, PhD)	BWH
2016-18	Member, K08 Advisory Committee (Jennifer Wu, PhD)	DFCI
2016-	Member, Center for Patient-Derived Models Advisory Board	DFCI
2016-2019	Advisor and Member, Doctoral Advisory Committee (Chen Lossos)	Harvard BBS Program
2017–2018	Member, Claudia Adams Barr Program Presidential Advisory Committee	DFCI
2017-2018	Member, Strategic Planning Research Advisory Group	DFCI
2018	Member, Prevention & Early Detection Strategic Planning Working Group	DFCI
2018	Member, Breakthrough Tiger Teams Initiative Steering Committee	DFCI
2018-19	External Academic Member, Postdoctoral Advisory Committee (Connie Larson, PhD)	AstraZeneca
2018-19	Member, K99/R00 Advisory Committee (Shruti Bhatt, PhD)	DFCI
2018	Chair, Dissertation Examining Committee (Andrew Giacomelli)	Harvard BBS Program
2018-	Member, Myeloid Malignancies Program Project (NCI P01; P.I., Benjamin Ebert) Internal Advisory Board	DF/HCC
2019	Member, Dissertation Examining Committee (Lisa Witten)	Harvard BBS Program

2019-	Member, Chronic Lymphocytic Leukemia Program Project (NCI P01; P.I. Catherine Wu) Internal Advisory Board	DFCI
2019	Member, Center Scientific Council	DF/HCC
2019	Member, Task Force on Patient Specimen Derivatives	DFCI
2019	Member, Cell Therapy Search Committee	Department of Medical Oncology, DFCI
2019-	Member, Internal Advisory Board Comprehensive Partnership to Advance Healthy Equity	UMass Boston – DF/HCC Partnership
2019-	Member, Mechanisms and Therapy of Chronic GvHD Program Project (NHLBI P01; P.I., Corey Cutler) Internal Advisory Board	DFCI
2019-2021	Member, Doctoral Advisory Committee (Inchul You)	Harvard Chemical Biology Program
2019-	Member-at-large, Faculty Council	HMS/Harvard School of Dental Medicine
	2020-	Subcommittee on Standing Committees, Member
	2020-2021	Subcommittee on Sustainability, Co-Chair
2020-2022	Member, Executive Committee for Research	DFCI
2020	External Member, Dissertation Examining Committee (Yunpeng Liu)	Department of Biology, MIT
2020	Member, Dissertation Examining Committee (Catherine Gutierrez)	Harvard BBS Program
2020-	Member, Research Misconduct Investigation Committee	HMS
2020-	Member, Fellow Mentorship Committee (Cynthia Hahn, MD, PhD)	DFCI
2020	External Member, Dissertation Examining Committee (Katherine Antel, MD)	University of Cape Town, South Africa
2021	Member, Dissertation Examining Committee (Mitchell Liebowitz)	Harvard BBS Program

2021	Member, Dissertation Examining Committee (Connor Clairmont)	Harvard BBS Program
2019-	Member, Doctoral Advisory Committee (Alex Miller)	Health Sciences and Technology Program Harvard-MIT
2019-	Member, Steering Committee	Nascent Transcriptomics Core HMS
<u>National</u>		
2008-	Member, Executive Committee	RITN
2008–2011	Member, Scarce Resources After an Improvised Nuclear Device Committee	US Department of Health and Human Services (DHHS)
2009	Member, Chemical, Biological, Radiological, Nuclear, Medical Countermeasure Advisory Group	Biomedical Advanced Research Development Authority (BARDA)
2012-2016	Member, Panel of Scientific Advisors	Lymphoma Research Foundation (LRF)
	2016-2019 2018	Member, Scientific Advisory Board Visiting Faculty, Lymphoma Clinical Research Mentoring Program
2013-2014	Member, Acute Radiation Syndrome Clinical Guidance Workshop	Office of Policy and Planning, DHHS
2014-2016	Member, Improvised Nuclear Device Antimicrobial Product-Specific Requirements Working Group	Office of Policy and Planning, DHHS
2014-2017	Member, National Preparedness and Response Science Board (NPRSB)	Office of the Assistant Secretary for Preparedness and Response (ASPR), DHHS
	2014-2015	Member, Working Strategies Working Group
	2016	Co-Chair, Strategic National Stockpile Review Working Group
2015-2017	Member, External Advisory Board, Centers for Medical Countermeasures Research Consortium (CMCRC)	National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD
2016	Co-Chair, Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Review Working Group	Office of the ASPR, NPRSB, DHHS



2017	Member, Scientific Advisory Board International Conference on Lymphoma	American Association for Cancer Research (AACR)
2017-	Member, Acute Myelogenous Leukemia Working Group, Cancer Summit	Commonwealth Foundation
2017-	Member, GeneLab Analysis Working Group	National Aeronautics and Space Administration (NASA)
2018-	Member, Medical and Scientific Committee	Leukemia and Lymphoma Society
2018-	Member, Therapy Acceleration Program Committee	Leukemia and Lymphoma Society
2018-	Member, Lymphoma Committee	Alliance for Clinical Trials in Oncology
2018-	Member, Disease Working Group PTCL Sequencing Project	Center for Cancer Genomics, NCI
2018	Member, T-cell Lymphoma Working Group	NCI
2018-	Member, External Advisory Board	Lymphoma Specialized Program of Regional Excellence (SPORE) Washington University in St. Louis
2019-2021	Member, Advisory Board	Institute for Clinical and Economic Review (ICER)
2019-2020	Member, Scientific Advisory Board 2 <sup>nd</sup> International Conference on Lymphoma	American Association for Cancer Research (AACR)
	2020	Abstract Reviewer
2019	Member, Review Panel	Radiation/Nuclear Medical Countermeasure Product Development Support, RFP- NIAID-NIHAI201800019
2020	Chair and Member, <i>Ad hoc</i> Promotion Committee for Dr. Chun-Wei (David) Chen	City of Hope Medical Center Duarte, CA
2018-	Member, External Advisory Board	Program Project Grant in Lymphoma (P01) WCMC and MD Anderson Cancer Center

### International

2017	Member, External Review Board	German Cancer Research Center Scientific Review (Deutsches Krebsforschungszentrum; DKFZ)
------	-------------------------------	--

2017-2018	Member, External Advisory Board	BIOTEchnological Securitization Università degli Studi di Brescia, Italy
2020-	Member, AITL Working Group	International Rare Cancer Initiative Cancer Research UK/NCI/EORTC
2021-	Member, Change Champions Committee	Women in Lymphoma Snowdome Foundation, Australia

### Professional Societies

1997	Member, Alpha Omega Alpha Medical Honor Society 1997-1998	Student Chapter President, George Washington University
1997-2008	Member, American Medical Association (AMA)	
1997-2008	Member, American College of Physicians (ACP)	
2000-2008	Member, American Society of Clinical Oncology (ASCO)	
2000-	Member, American Society of Hematology (ASH)	
	2010-2011	Member and Session Chair, Abstract Selection Committee
	2011-2015	Member, Committee on Scientific Affairs
	2013-2014	Co-Chair, Steering Committee, 2014 Meeting on Lymphoma Biology
	2015-2016	Member, Steering Committee, 2016 Meeting on Lymphoma Biology
	2017-	Member, Data Hub Oversight Group
	2018-	Member, Committee on Lymphoid Biology Vice-Chair (2019) and Chair (2020)
	2018	ASH-a-Palooza 2018 Blood Buddies

2001-2008	Member, Infectious Diseases Society of America (IDSA)	
2002-	Member, American Association for Cancer Research	
	2013-2014	Member, Annual Meeting Program Committee
	2019-2020	Co-Chair, Second AACR International Meeting on Advances in Malignant Lymphoma
2005-2016	Member, American Society for Blood and Marrow Transplantation	
2013-	Elected Member, American Society for Clinical Investigation (ASCI)	
2020-	Member, Sigma Xi Scientific Research Honor Society	

### Grant Review Activities

2008-2009	Member, Advanced Therapeutics for Treating Neutropenia Review Panel	BARDA
2010-2015	Member, DNA Mechanisms and Cancer Review Committee	American Cancer Society
2012	External Reviewer	Children with Cancer UK
2012	External Reviewer	Ireland Health Research Board
2012, 2017	Member, Review Committee	Dana-Farber/Novartis Drug Discovery Program
2013-2014	<i>Ad hoc</i> Member, Study Section, Radiation Therapeutics and Biology	Center for Scientific Review (CSR)
	2014-2016	Standing Member
2013	Member, Seed Grant Review Committee	Harvard Stem Cell Institute
2013	External Reviewer	German-Israeli Foundation for Scientific Review and Development

2013	External Reviewer, Clinical Trials Working Group	National Cancer Institute (NCI)
2013	External Reviewer	Dutch Cancer Society
2014	External Reviewer	Leukemia and Lymphoma Research UK
2015-2017	Member, Career Development Study Section	Leukemia and Lymphoma Society (LLS)
2016	Member, R50 Special Emphasis Panel ZCA1 SRB-C (A1) S Pediatric Provocative Questions Study Section	CSR
2016	External Reviewer	Fondation contre le Cancer Grant
2016-17	Member, Bridge Program Study Section	DFCI/MIT
2016-19	Member, Translational Research Program Study Section	LLS
	2017-19	Chair
2016-	Reviewer, Career Development Program	Lymphoma Research Foundation
2018	External Reviewer	Cancer Research UK
2018	External Reviewer	Luxembourg National Research Fund
2018	Standing Member	Barr Review Committee, DFCI
2018	External Reviewer, SCOR Program	LLS
2018	External Reviewer	Bloodwise, United Kingdom
2018, 2020, 2021	External Reviewer	National Center for Tumor Diseases (NCT) Heidelberg, Germany
2018	External Reviewer	Biomedical Commission of Kom op tegen Kanker (Stand up to Cancer), Belgium
2018	External Reviewer	Single cell approaches for the study of oncogenic processes ITMO Cancer of the French National Alliance for Life and Health Sciences
2019	External Reviewer	Dotan Hemato-Oncology Research Center Tel Aviv University, Israel

2020	<i>Ad hoc</i> Reviewer	Harvard Immunoengineering to Improve Immunotherapy Center, Boston, MA
2021	<i>Ad hoc</i> Reviewer	Vienna Science and Technology Fund Vienna, Austria
2021	<i>Ad hoc</i> Member, Pediatric In Vivo Testing Program, 2021/05 ZCA1 GRB-I (M1) R	NCI Center for Scientific Review
2021	<i>Ad hoc</i> Member, Cancer Drug Development and Therapeutic Study Section	NCI Center for Scientific Review
2021	External Reviewer Mantle Cell Lymphoma Research Initiative	LLS

## Editorial Activities

### ***Ad hoc* Reviewer**

*American Journal of Hematology*  
*Biosecurity ad Bioterrorism*  
*Blood*  
*Bone Marrow Transplantation*  
*Biology of Blood and Marrow Transplantation*  
*Cancer Cell*  
*Cancer Discovery*  
*Cancer Immunology Research*  
*Cancer Reports*  
*Cancer Research*  
*Cell*  
*Cochrane Library*  
*Genes and Development*  
*Genes, Chromosomes and Cancer*  
*Health Physics*  
*Infection Control and Hospital Epidemiology*  
*International Journal of Radiation Biology*  
*Journal of Clinical Investigation*  
*Journal of Experimental Medicine*  
*Journal of Infectious Diseases*  
*Journal of the American Medical Association*  
*Lancet*  
*Lancet Oncology*  
*Leukemia*  
*The Medical Letter*  
*Nature*  
*Nature Cancer*  
*Nature Genetics*  
*Nature Medicine*

*Nature Reviews Cancer*  
*New England Journal of Medicine*  
*Nucleic Acids Research*  
*PLoS Genetics*  
*Proceedings of the National Academy of Sciences*  
*Science Translational Medicine*  
*Scientific Advances*  
*Stem Cells*  
*Transplant Infectious Diseases*

### **Other Editorial Roles**

2012-2017	Consulting Editor	<i>Journal of Clinical Investigation</i>
2020	Guest Editor	<i>PLoS Genetics</i>

### **Honors and Prizes**

1996	Resident Travel Award for Outstanding Investigation	American Society of Hematology
1997	Award for Outstanding Resident Research	American College of Physicians
1997	Walter Freeman Research Award	George Washington University
1997	Paul L. Dewitt Award in Surgery	George Washington University
2000	Barbara H. Zucker Traveling Fellowship in Infectious Diseases	New York Presbyterian Hospital
2000	A. Lee Winston Senior Resident Award	New York Presbyterian Hospital
2001	John Mendelsohn Housestaff Teaching Award	Department of Medicine, MSKCC
2002	Fellow Travel Award	Infectious Diseases Society of America
2003	Fellow Travel Award	Society for Healthcare Epidemiology of America

2003	Clinical Scholars Research Fellowship	MSKCC
2004	Research Presentation Award	GlaxoSmithKline Fellow Forum
2005	Scholar-in-Training Award	AACR/AFLAC
2015	Medical Oncology Discovery Award	DFCI
2018-	Distinguished Investigator Award	Paul G. Allen Frontiers Group
2019-	Outstanding Investigator Award	NCI/NIH
2020	Mentor of the Year Award	Postdoctoral and Graduate Student Association, DFCI

## **Report of Funded and Unfunded Projects**

### **Funding Information**

#### **Past**

- 2004-2007      Chromosomal Translocations after RAG-mediated DNA-double-strand Breaks  
Leukemia and Lymphoma Society Research Fellow Award, 5415-05  
PI  
The major goal of the study was to determine whether DNA breaks induced during V(D)J recombination participate in reciprocal chromosomal translocations in a murine embryonic stem cell model.
- 2005-2007      Assaying DNA Double-strand Break Repair with Zinc Finger Nucleases  
Patrick Byrne Fund Program for Cancer Research  
PI  
The major goal of the study was to establish a system for measuring the efficiency and precision of DNA double-strand break repair in primary human cells using zinc finger nucleases.
- 2006-2007      DNA Repair Defects and Treatment-related Cancer Among Patients with Hodgkin  
Lymphoma  
ASCO Young Investigator Award  
PI  
The major goal of the study was to determine whether patients who develop secondary malignancies after treatment for Hodgkin Lymphoma have predisposing abnormalities in the precision of DNA double-strand break repair.

- 2006-2008     Assaying Risk for Secondary Leukemia Among Patients with Breast Cancer  
MSKCC/Chanel Survivorship Research Award  
PI  
The major goal of the study was to determine whether patients who develop secondary leukemia after treatment for breast cancer have predisposing abnormalities in the precision of DNA double-strand break repair.
- 2006-2011     Zinc Finger Nucleases for Assaying DNA Repair  
Burroughs-Wellcome Fund Career Award in the Biomedical Sciences, 57720-20180  
PI  
The major goal of the study was to establish a system for assaying the precision of DNA double-strand break repair across diverse populations using zinc finger nucleases.
- 2008-2010     Factors that Promote Chromosomal Translocation Formation  
Claudia Adams Barr Innovative Basic Science Research Program  
PI  
The major goal of this study was to identify genetic factors that promote chromosomal translocation formation using a lentiviral shRNA screen in a mouse model of genomic rearrangements.
- 2009            Antibody Development Against the Novel Oncogene CRLF2  
Dunkin' Donuts Rising Stars Program  
PI  
The major goal of this study was to develop reagents with specificity against the leukemia oncogene CRLF2.
- 2009-2011     DNA Double-strand Break Repair in Human Pluripotent Stem Cells  
Harvard Stem Cell Institute Seed Grant, SG-0048-09-00  
PI  
The major goal of this study was to define the phenotype of DNA double-strand break repair in human embryonic and induced pluripotent stem cells from healthy donors and patients with defects in repair.
- 2010-2012     DNA Repair and Leukemogenesis on Down Syndrome  
ASH Junior Faculty Scholar Award  
PI  
The major goal of the study was to identify aberrations in DNA repair that contribute to leukemogenesis in patients with Down Syndrome.
- 2010-2012     Functional Oncogene Identification  
Stand Up to Cancer (S<sup>↑</sup>2C<sup>®</sup>)/AACR Innovative Research Grant SU2C-AACR-IRG0409  
PI  
The major goal of this study was to identify novel DNA and mRNA alterations in hematologic tumors.
- 2010-2014     Functional Oncogene Identification  
American Cancer Society RSG-10-181-01-RMC  
PI



The major goal of this study was to identify novel DNA and m RNA Alterations in tumor specimens.

- 2011-2012 Targeting the Cytokine Receptor CRLF2 in Acute Lymphoblastic Leukemia (ALL)  
DFCI-Novartis Drug Development Program  
PI  
The major goal of this study was to target CRLF2 with small molecule and monoclonal antibody inhibitors.
- 2012-2015 Targeting Acute Lymphoblastic Leukemia with Trisomy 21  
Leukemia and Lymphoma Society Translational Research Program  
Co-PI with John Crispino, Northwestern University  
The major goal of this study was to target ALL with trisomy 21 using inhibitors of HSP90 and DYRK1A.
- 2013-2014 Targeting BAFF-R in Mantle Cell Lymphoma  
Novartis Institute for Biomedical Research  
PI  
The major goal of this study was to determine the epidemiology, function and target value of BAFF-R on mantle cell lymphoma.
- 2013-2015 Targeting HSP90 in Acute Lymphoblastic Leukemia  
William Lawrence and Blanche Hughes Foundation  
PI  
The major goal of this study was to assay the mechanisms underlying treatment response and resistance among patients with acute lymphoblastic leukemia treated with the HSP90 inhibitor AUY922.
- 2013-2016 Primary Leukemia Xenograft Repository  
DFCI Departments of Medical Oncology and Pediatric Oncology  
PI  
The major goal of this effort was to establish a repository of patient-derived xenograft models of leukemia.
- 2015-2017 Targeting Minimal Residual Disease in Acute Leukemias  
Dana-Farber/Koch Institute Bridge Program  
Co-PI (with Scott Manalis, PhD)  
The major goal of this study is to utilize mass accumulation rate measurements as predictors of therapeutic efficacy in leukemia specimens.
- 2015-2017 Targeting Functional Alterations in Lymphoid Malignancies and Breast Cancer  
DFCI/Novartis Drug Development Program  
PI  
The major goal of this study is to develop novel treatment approaches in lymphoid tumors and breast cancer.
- 2016-2017 CRLF2 Signaling in B-cell Acute Lymphoblastic Leukemia  
NIH/NCI 3 R01 CA151898-06A1W1  
PI

The major goal of this administrative supplement is to develop patient-derived xenografts of leukemia from underrepresented minorities.

- 2013-2018 Defining the Molecular Ontogeny of Follicular Lymphoma  
Leukemia and Lymphoma Society Scholar  
PI (\$550,000)  
The major goal of this study is to define the hierarchy of mutational acquisition that leads to follicular lymphoma across a large panel of samples.
- 2013-2018 Trisomy 21 and Acute Lymphoblastic Leukemia  
NIH/NCI 1 R01 CA172387  
PI (\$1,250,000)  
The major goal of this study is to determine the contribution of trisomy 21 to ALL.
- 2016-2018 Targeting Anti-Apoptotic Proteins in Peripheral T-cell Lymphomas  
Abbvie, Inc.  
PI (\$250,000)  
The major goal of this sponsored effort is to utilize inhibitors of BCL2, BCL-xL and MCL1 in xenograft models of PTCL.
- 2017-2018 Defining the Activity of MDM2/MDM4 Inhibition in T Cell Lymphoma  
Aileron, Inc.  
PI (\$205,000) (Overall PI: Ross Levine, MSKCC)  
This study uses in vitro and in vivo models to define the activity of a novel stapled peptide alone and in combination with chemotherapy.
- 2017-2018 Preclinical Evaluation of AZD5991 and AZD4320 in T-cell Lymphomas  
AstraZeneca, Inc.  
PI (\$125,000)  
This study uses in vitro and in vivo models to define the activity of inhibitors of BH3 family proteins alone and in combination with chemotherapy.
- 2017-2018 Single Cell Growth Assay for Residual Cells in Acute Lymphoblastic Leukemia  
NIH/NCI 5-R33CA191143-03 (MIT)  
Consortium PI (Overall PI: Scott Manalis, MIT)  
The major goal of this study is to build on a previous R21 to develop a serial assay capable of measuring growth of large numbers of minimal residual disease cells in parallel after drug treatment.
- 2016-2018 Inducing Non-Cell Autonomous Killing to Overcome Drug Resistance in Double-hit Lymphoma  
Dana-Farber/Koch Institute Bridge Program  
Co-PI (with Ann LaCasce of DFCI; Michael Hemann of Koch Institute) (\$750,000)  
The major goal of this clinical study is to define the activity and mechanisms of cyclophosphamide/alemtuzumab in patients with double-hit lymphoma.
- 2017-2019 Development of Small Molecule BTK Degradors for the Treatment of Mantle Cell Lymphomas  
DFCI Accelerator Grant

Co-PI with Nathanael Gray, DFCI (\$250,000)

This study develops chemical matter that targets BTK for degradation through a Cereblon-dependent mechanism and validates activity in vitro and in vivo.

- 2018-2019    Advanced diagnostics for lymphoma in low- and middle-income countries  
New Idea Award  
Leukemia and Lymphoma Society  
PI (\$75,000)  
This study seeks to validate a transcriptional diagnostic for lymphoma in Guatemala.
- 2010-2020    CRLF2 Signaling in Acute Lymphoblastic Leukemia  
NIH/NCI 1 R01 CA151898  
PI (Direct Funding: \$1,250,000)  
The major goal of the study is to determine and target the mechanisms of signaling downstream of CRLF2 in precursor B-cell acute lymphoblastic leukemia.
- 2015-2020    Translational Discovery in Peripheral T-cell Lymphomas  
Specialized Center of Research (SCOR), Leukemia and Lymphoma Society 7011-16  
PI (\$4,133,000)  
The major goal of this collaborative center is to develop new therapies that rationally target PTCL and advance these into clinical trials.
- 2017-2019    Targeting JAK2 with Type II Inhibitors  
Prostate Cancer Foundation  
PI (\$300,000)  
This study seeks to develop type II JAK2 inhibitors in collaboration with Nathanael Gray.
- 2018-2019    Use of an Implantable Microdevice for in Situ Drug Sensitivity Testing for  
Cutaneous Lymphoma  
Falk Medical Research Trust Catalyst Award  
Co-PI with Oliver Jonas (\$100,000)  
The major goal of this study is to advance an implantable microdevice for therapeutic selection in patients with cutaneous lymphoma.

### **Current**

- 2017-2022    Quantitative and Functional Characterization of Therapeutic Resistance in Cancer  
NCI U54 CA217377  
Co-PI, Projects 1 and 2 and Core 1 (PIs: Scott Manalis (Koch); Douglas Lauffenberger (Koch))  
This study uses bioengineering approaches to define cell intrinsic and non-cell autonomous mechanisms of therapeutic resistance in hematologic tumors.
- 2017-2022    Specialized Program of Regional Excellence (SPORE) in Myeloid Malignancies  
(Core 3: Biospecimens and Xenografts)  
NIH/NCI 1 P50 CA2069630-01A1  
Co-PI (Overall PI: Benjamin Ebert) (\$23,362)

The major goal of this study is to establish, characterize, and distribute xenograft models of myeloid diseases and facilitate pre-clinical trials.

- 2021-2022      Developmental Research Award  
NIH/NCI 1 P50 CA2069630 – DRP-20-01  
PI (\$100,000)  
The major goal of this project is to establish data using a blood circulation system for quantifying and tracking the transfer and engraftment of leukemia minimal residual disease between two mice.
- 2021-2026      Translational Discovery in Peripheral T-cell Lymphomas  
Specialized Center of Research (SCOR), Leukemia and Lymphoma Society 7026-21  
PI (\$3,200,000)  
The major goal of this collaborative center is to develop new therapies that rationally target PTCL and advance these into clinical trials.
- 2018-2021      Defining Vulnerabilities of MRD  
Paul G. Allen Frontiers Group Distinguished Investigator Award  
PI, DFCI (\$1,500,000)  
The major goal of this study is to establish strategies for isolating and functionally characterizing minimal residual disease from patients with lymphoma.
- 2018-2021      Point-of-care diagnostics for Lymphoma  
Celgene Cancer Care Links™ grant program  
PI (\$100,000)  
The major goal of this study is to establish a diagnostic laboratory in Guatemala City for transcription-based assessment of lymphoma subtype.
- 2018-2022      Randomized Phase 2 Trial in High-risk Relapsed Refractory Follicular Lymphoma  
NCI/Cancer Therapy Evaluation Program (CTEP) Biomarker, Imaging and Quality of Life Funding Program (BIQSFP)  
Co-Investigator (Overall PI: Charles Blanke, Oregon Health Sciences Univ.) (\$53,451)  
This study uses next-generation sequencing to define genetic correlates associated with response to second-line treatment of follicular lymphoma.
- 2019-2024      Informed combination strategies for peripheral T-cell lymphoma  
NIH/NCI P01 CA248384-01A1  
Overall PI, Project 3 PI, Admin Core PI (\$7,500,000)  
The primary goal of this program project grant is to establish new combination strategies within preclinical models that target peripheral T-cell lymphomas.
- 2019-2026      Targeting high-risk lymphoid neoplasms  
NIH/NCI R35 CA231958-01A1  
PI (\$4,200,000)  
The primary goal of this NCI Outstanding Investigator Award is to develop new strategies to target T-cell lymphomas, including adoptive cellular therapies and precision diagnostics.
- 2019-2021      Defining traffic patterns in lymphoma metastasis

Claudia Adams Barr Innovative Basic Science Research Program

PI (\$520,000)

The primary goal of this award is to utilize rapid autopsy specimens to define trafficking of transcriptionally and genetically distinct subclones between sites of lymphoma.

**Training Grants and Mentored Trainee Grants**

- 2014- Training Program in Molecular Hematology  
NIH T32 HL116324 (PI: Nancy Berliner, BWH)  
Faculty  
The goal of this grant is to train fellows in Hematology, with a focus on the investigation of benign hematologic disorders in the areas of red cell disorders, iron metabolism, hemostasis and thrombosis, and neutrophil disorders, as well as hematologic malignancies such as leukemia, myelodysplasia and myeloproliferative neoplasms.
- 2015- Graduate Training in Cancer Research  
NIH T32 CA009172 (PI: James DeCaprio, DFCI)  
Faculty  
The purpose of this grant is to provide research training for postgraduate physicians who desire a career in academic oncology.
- 2015- Pathophysiology of Human Blood Cells  
NIH T32 HL007574  
Faculty (PI: David Williams, BCH)  
The goal of this training program is to provide PhD and PhD-post-doctoral level research experiences and scholarly research training in Hematology/Oncology, with the goal of establishing trainees as independent investigators making substantive contributions to biomedical research.
- 2017- Clinical Research Career Development Program  
NIH K12 CA087723  
Mentor (PI: Bruce Chabner, MGH)  
The objective of this program is to produce a next generation of clinical investigators who work at the interface between laboratory science, population science, and clinical medicine in molecular oncology.

**Projects Submitted for Funding:**  
**Report of Local Teaching and Training**

**Teaching of Students in Courses**

2009-2011, 2013, 2017 2021	Taking the Next Step, Medicine/Session Panelist Undergraduate students	University of Chicago, Chicago, IL  2 hours per event
----------------------------------	--	---

## HMS/HSDM/DMS

2011-2012	Analysis of the Biological Literature (BBS 230) Graduate students	HMS 30 hours annually
2011, 2013	Biology of the Cancer Cell (Cell Biology 212) Graduate students	HMS 2 hours annually
2012-2019	Cancer Biology (BBS 375) Graduate students in the Weinstock lab	HMS 40 hours annually
2014	Critical Thinking and Research Proposal Writing (BBS 330) Graduate students	HMS 30 hours
2017	Lymphoma, Hematology course HT080.0 Medical students, Health Sciences and Technology (HST) Program	HMS 1 hour
2017	Plasma Cell Disorders, Hematology HT080.0 Medical students, HST Program	HMS 1 hour
2018	Conduct of Science (Med-Sci 300QC) Graduate students	HMS 30 hours
2019	Cancer Biology and Therapeutics: High Impact Cancer Research Capstone Mentor	HMS 4 hours

## Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs)

2001-2007	Medicine Housestaff Conference Department of Medicine interns and residents	MSKCC 4 hours contact time annually
2001-2007	Morning Report Department of Medicine interns and residents	MSKCC 4 hours contact time annually
2014	Hematology/Oncology Lecture Series Hematology/Oncology fellows	DFCI 1 hour lecture
2021	Special Workshop How to Not Not Get a Grant	DFCI 2 hours

## Instructors and Junior Faculty

2022	Lymphoma Scientific Research Mentoring Program Fellows and Junior Faculty	Lymphoma Research Foundation 4 days, Scottsdale, AZ
------	---	--

## Laboratory and Other Research Supervisory and Training Responsibilities

2008-	Supervision of postdoctoral research fellows and students / DFCI	Several hours weekly, 12 months per year
2014-2017	Faculty, Master of Medical Sciences in Biomedical Informatics / HMS	Four hours per year

## Formally Mentored Harvard Medical, Dental and Graduate Students

2012-2019	Jacob Layer, PhD / Research Scientist, eGenesis Bio, Cambridge, MA Graduate student in Harvard Biological and Biomedical Sciences Program focused on identifying modulators of chromosomal translocations. Recipient of a Graduate Research Fellowship from the National Science Foundation.
2015-2019	Chen Lossos, PhD / Medical Student, HMS, Boston, MA MD/PhD student in HMS BBS Program focused on identifying targetable nodes in B cell lymphomas.

## Other Mentored Trainees and Faculty

2007-2008	Ashwin Jathevadem, MD / Private Practice (Infectious Diseases), Englewood, NJ <i>Career stage:</i> Clinical Infectious Disease Fellow // <i>Mentoring role:</i> Mentor <i>Accomplishments:</i> Mentored for one year of research fellowship investigating the epidemiology of infectious complications among autologous stem cell transplant recipients, which resulted in two first-author publications ( <i>Bone Marrow Transplantation</i> , <i>Biology of Blood and Marrow Transplantation</i> ).
2008-2011	Hua Fung, PhD / Research Scientist, Case Western University, Cleveland, OH <i>Career stage:</i> Postdoctoral Fellow // <i>Mentoring role:</i> Mentor <i>Accomplishments:</i> Worked on a research project focused on DNA repair in human pluripotent stem cells. Published a first-author manuscript in <i>PLoS One</i> describing the phenotype of DNA double-strand break repair in human pluripotent stem cells.
2008-2017	Akinori Yoda, PhD / Research Scientist, Osaka University, Osaka, Japan <i>Career stage:</i> Postdoctoral Fellow // <i>Mentoring role:</i> Mentor <i>Accomplishments:</i> Worked on a project focused on oncogene identification and CRLF2 biology. Published first-author manuscripts in <i>Proceedings of the National Academy of Sciences USA (PNAS)</i> , <i>Nature Medicine</i> , <i>PLoS One</i> , and <i>Blood</i> and co-authorship on multiple manuscripts. Recipient of the William P. Evans Foundation fellowship.

- 2009 Kartik Mani, M, PhD / Resident, Radiation Oncology, Montefiore Medical Center, Bronx, NY  
*Career stage:* Summer medical student // *Mentoring role:* Mentor  
*Accomplishments:* Worked on a research project focused on diagnostic assay development for CRLF2. Recipient of an American Society of Hematology Travel Award. Co-author on a manuscript in *PNAS*.
- 2009 David Miller, MD / Resident, Dermatology, Columbia University, New York, NY  
*Career stage:* Summer medical student // *Mentoring role:* Mentor  
Summer student in the Weinstock laboratory focused on CRLF2 mutagenesis screen. Recipient of an American Society of Hematology Travel Award.
- 2009-2012 Chaitali Dutta, PhD / Scientist II, Dicerna Pharmaceuticals, Inc., Cambridge, MA  
*Career stage:* Postdoctoral Fellow // *Mentoring role:* Mentor  
*Accomplishments:* Worked on a project focused on the relationship between BCL2 and genomic instability. Published a first-author manuscript in *Cancer Research* and co-authored multiple manuscripts. Recipient of an American Association for Cancer Research Travel Award.
- 2009-2012 Oliver Weigert, MD / Professor, Medicine, Ludwig-Maximilian University, Munich, Germany  
*Career stage:* Postdoctoral Fellow // *Mentoring role:* Mentor  
*Accomplishments:* Worked on a project that was focused on oncogene identification and kinase inhibitor resistance. Published first-author manuscripts in the *Journal of Experimental Medicine*, *Cancer Discovery*, and *Blood*, and co-authored multiple manuscripts. Now leads his own laboratory at University of Munich.
- 2010-2012 Diederik van Bodegom, PhD / Senior Scientist, Cell Line Development and Molecular Biology, Oncobiologics, Inc.  
*Career stage:* Postdoctoral Fellow // *Mentoring role:* Mentor  
*Accomplishments:* Worked on a project focused on CRLF2-mediated leukemogenesis. Published first-author manuscript in *Blood* and co-author on multiple manuscripts. Recipient of a travel award from the American Society of Hematology.
- 2010-2014 Andrew Lane, MD, PhD / Associate Professor, HMS and DFCI  
*Career stage:* Hematology/Oncology Fellow and Instructor // *Mentoring role:* Mentor  
*Accomplishments:* Worked in my lab on a project that was focused on novel mechanisms of leukemogenesis. Co-author on multiple manuscripts and lead author on manuscripts in *Nature Genetics* and *Nature Medicine*. Recipient of a Leukemia and Lymphoma Society Special Fellow Award, a Postdoctoral Fellowship from the Lauri Strauss Foundation, a Young Investigator Award from the American Society for Clinical Oncology, a fellowship from Alex Lemonade Stand Foundation, and a K08 award from NCI. Now leads his own laboratory at DFCI/HMS.
- 2010-2018 Tovah Day, PhD / Assistant Professor, Biology, Northeastern University  
*Career stage:* Postdoctoral Fellow and Junior Faculty // *Mentoring role:* Mentor  
*Accomplishments:* Working on a project that is focused on polysomy 21 and leukemogenesis. Recipient of postdoctoral fellowships from the American Cancer Society and Alex Lemonade Stand Foundation, a DFCI Claudia Adams Barr Program for Cancer



Research Award, and a K01 award from National Institute of Aging, NIH. Published first-author manuscript in *Nature Communications*, two senior author manuscripts in *PNAS* and co-author on multiple manuscripts. Now leads her own laboratory at Northeastern University.

- 2011-2012 Nobuaki Shindou, PhD / Staff Scientist at Astellas, Inc., Tokyo, Japan  
*Career stage:* Visiting Scientist // *Mentoring role:* Mentor  
*Accomplishments:* Worked on a project that focused on oncogene identification. Published a first-author manuscript in *PLoS One*.
- 2011-2013 Gina Yu / Research Assistant, Beth-Israel Deaconess Medical Center (BIDMC)  
*Career stage:* Undergraduate Student, Harvard College // *Mentoring role:* Mentor  
*Accomplishments:* Performed her thesis project focused on the mechanisms of translocation formation. Received an American Society of Hematology Trainee Research Award.
- 2012-2014 Oreofe Odejide, MD / Assistant Professor, Medicine, HMS  
*Career stage:* Hematology/Oncology Fellow // *Mentoring role:* Mentor  
*Accomplishments:* Worked on a project focused on translational therapeutic studies in mature lymphoid malignancies. First-author of a plenary paper in *Blood*.
- 2013-2016 Elizabeth Townsend, PhD / Scientist, Forma Therapeutics  
*Career stage:* Postdoctoral Fellow // *Mentoring role:* Mentor  
*Accomplishments:* Worked on a project focused on epigenetic alterations in progenitor B cell neoplasms. Recipient of a T32 training award and Alex Lemonade Stand Foundation Young Investigator Award. First-author of manuscript in *Cancer Cell* and co-author on multiple manuscripts.
- 2013-2018 Mark Murakami, MD / Assistant Professor, Medicine, HMS and Physician, Medical Oncology, DFCI  
*Career stage:* Hematology/Oncology Fellow and Junior Faculty // *Mentoring role:* Mentor  
*Accomplishments:* Working on a project that is focused on targeting B cell leukemias. Recipient of an American Cancer Society Fellowship and Translational Research Training in Hematology Award from the American Society of Hematology, and a K08 award from NCI. First-author of manuscripts in *Cancer Cell* and *Nature Biotechnology*, a News and Views in *Nature*, and co-author on multiple manuscripts. Now leads his own laboratory at DFCI and HMS.
- 2013-2014 Jerome Tamburini, MD / Professor, Hematology-Oncology, University of Geneva.  
*Career stage:* Visiting Scientist // *Mentoring role:* Mentor  
*Accomplishments:* Performed a sabbatical in my laboratory with a focus on modeling of BCR-ABL-rearranged B-cell leukemias. Co-author on manuscript in *Nature Medicine* and senior author on manuscript in *Cell Reports*.
- 2013-2019 Loretta Li, MD / Assistant Professor, Pediatrics, Northwestern University Medical Center  
*Career stage:* Pediatric Hematology-Oncology Fellow and Junior Faculty // *Mentoring role:* Mentor  
*Accomplishments:* Working on a research project focused on targeting JAK2 in acute lymphoblastic leukemia. Recipient of a Damon Runyon Physician Scientist Award and

Young Investigator Award from CureSearch for Children's Cancer Foundation. First author of manuscript in *Cancer Cell* and co-author on multiple manuscripts. Now leads her own laboratory at Northwestern.

- 2013-2021 Abner Louissaint, MD, PhD / Assistant Professor, Pathology, HMS, Assistant in Pathology, MGH  
*Career stage:* Junior Faculty // *Mentoring role:* Mentor  
*Accomplishments:* Working on a project that is focused on the genetics of rare B-cell neoplasms. Recipient of a K23 award from NCI/NIH and an Amos Fellowship from the American Society of Hematology. First author on manuscripts in *Blood* and *J Investigative Dermatology*. Now leads his own laboratory at MGH and HMS.
- 2014-2016 Elizabeth Morgan, MD / Assistant Professor, Pathology, HMS  
*Career stage:* Junior Faculty // *Mentoring role:* Mentor  
*Accomplishments:* Worked on a project that is focused on the biology of lymphoma in Sub-Saharan Africa. Recipient of an HMS Shore Award. First author of a manuscript in *Blood Advances*.
- 2014- Samuel Ng, MD, PhD / Instructor, Medicine, HMS, and Physician, Medical Oncology, DFCI  
*Career stage:* Hematology/Oncology Fellow and Junior Faculty // *Mentoring role:* Mentor  
*Accomplishments:* Working on a project focused on the genetics of T cell lymphomas. Recipient of a T32 training award, FLAIR award, American Cancer Society Fellowship, and Translational Research Training in Hematology Award from the American Society of Hematology. Recipient of a KL2/Catalyst Medical Research Investigator Training (cMeRIT) award and K08 award from the NCI and a Fellow to Faculty Scholar Award from ASH. First author of manuscripts in *Blood* and *Nature Communications*. Now leads his own laboratory at BWH and HMS.
- 2014-2017 Caron Jacobson, MD / Assistant Professor, Medicine, HMS  
*Career stage:* Junior Faculty, Lymphoma Program // *Mentoring role:* Mentor  
*Accomplishments:* Worked on research focused on translating discoveries from my laboratory into clinical trials. Recipient of a KL2/cMeRIT award from the NCI. Recipient of a Cancer Therapy Evaluation Branch (CTEP) Young Investigator Award for a trial of AT13387 building on work from my laboratory. First author of a manuscript in *Blood*.
- 2015-2018 Amanda Christie / Research Scientists, Astra Zeneca  
*Career stage:* Master's Candidate, HMS // *Mentoring role:* Mentor  
*Accomplishments:* Worked as a Principal Research Technician in my laboratory while completing Master's courses. Co-author on 10 manuscripts. Currently employed by Astra Zeneca, Inc.
- 2015-2018 Raphael Koch, MD / Assistant Professor, University of Göttingen  
*Career stage:* Postdoctoral Fellow // *Mentoring role:* Mentor  
*Accomplishments:* Worked on a project focused on genetic abnormalities and signaling in T cell lymphomas. Recipient of a DFG fellowship from the German Government. First author of a manuscript in *Blood* and co-senior author of a manuscript at *Nature Communications*. Now leads his own laboratory at University of Göttingen.

- 2015-2018 Noriaki Yoshida, MD / Assistant Professor, Hiroshima Red Cross and Atomic Bomb Survivors Hospital  
*Career stage:* Postdoctoral Fellow // *Mentoring role:* Mentor  
*Accomplishments:* Focused on genetic abnormalities and signaling in T cell lymphomas. Recipient of a Japanese Science fellowship. First author of manuscripts in *Blood*, *Cancer Discovery* and *Nature Communications*. Now leads his own laboratory at Hiroshima University.
- 2016-2019 Edward Brierchek, MD / Oncology Fellow, Fred Hutchinson Cancer Research Center  
*Career stage:* Medical Resident (BMC) // *Mentoring role:* Mentor  
*Accomplishments:* Working with my laboratory on approaches to improve care of patients with lymphoma in Guatemala. Recipient of a Fulbright Scholar Award from the US State Department and Young Investigator Award from the Conquer Cancer Foundation. Currently a Hematology/Oncology Fellow at Fred Hutchinson Cancer Research Center.
- 2016- Salvia Jain, MD / Assistant Professor, Medicine, HMS,  
*Career stage:* Research Fellow // *Mentoring role:* Mentor  
*Accomplishments:* Working on a project focused on targeting innate immunity in T-cell lymphomas. Recipient of a T-cell Leukemia Lymphoma Foundation Young Investigator Grant and NCI K08. First author of a manuscript in *Blood*. Now leads her own laboratory at MGH and HMS.
- 2017- Fabiola Valvert Gamboa, MD / Staff Physician, Instituto de Cancerologica-INCAN, Guatemala City, Guatemala  
*Career stage:* Attending Physician // *Mentoring role:* Mentor  
*Accomplishments:* Working on a project focused on novel diagnostics for lymphoma in lower- and middle-income countries. Recipient of an American Society of Hematology Global Research Award.
- 2017- Gongwei Wu, PhD / Postdoctoral Fellow, Dana-Farber Cancer Institute and HMS  
*Career stage:* Research Fellow // *Mentoring role:* Mentor  
*Accomplishments:* Working on a project focused on chromosomal rearrangements in T-cell lymphomas. Recipient of a Leukemia and Lymphoma Society Fellowship.
- 2017- Wenchao Wu, PhD / Postdoctoral Fellow, Dana-Farber Cancer Institute and HMS  
*Career stage:* Research Fellow // *Mentoring role:* Mentor  
*Accomplishments:* Working on a project focused on mechanisms of action of targeted therapies in T-cell lymphomas.
- 2018- Ajit Johnson, PhD / Postdoctoral Fellow, Dana-Farber Cancer Institute and HMS  
*Career stage:* Research Fellow // *Mentoring role:* Mentor  
*Accomplishments:* Working on strategies to image and computationally deconvolute the lymphoma microenvironment. Recipient of an NCI K99/R00 award.
- 2018-19 Cedric Menard, PhD / Staff Scientist, University of Rennes, France  
*Career stage:* Research Fellow // *Mentoring role:* Mentor  
*Accomplishments:* Investigated strategies to model and target the lymphoma immune microenvironment.

- 2019- Lydie DeBaize, PhD / Postdoctoral Fellow, Dana-Farber Cancer Institute and HMS  
*Career stage:* Research Fellow // *Mentoring role:* Mentor  
*Accomplishments:* Working on engineering and bioinformatic strategies to identify very rare minimal residual lymphoma cells. Recipient of a Lymphoma Research Foundation Fellowship.
- 2019- Ran Xu, PhD / Postdoctoral Fellow, Dana-Farber Cancer Institute and HMS  
*Career stage:* Research Fellow // *Mentoring role:* Mentor  
*Accomplishments:* Working on strategies to target minimal residual disease in lymphomas.
- 2019- Tayla Heavican, PhD / Postdoctoral Fellow, Dana-Farber Cancer Institute and HMS  
*Career stage:* Research Fellow // *Mentoring role:* Mentor  
*Accomplishments:* Working on combination strategies to eradicate T-cell lymphomas.
- 2020- Katherine Antel, MD, PhD / Assistant Professor, University of Cape Town  
*Career stage:* Assistant Professor // *Mentoring role:* US-based co-Mentor  
*Accomplishments:* Recipient of an NCI K43 Fogarty Award. Working on combination strategies to eradicate T-cell lymphomas.
- 2021- Fabienne Lucas, MD, PhD / Pathology Resident, Brigham and Women's Hospital  
*Career stage:* Resident // *Mentoring role:* Mentor  
*Accomplishments:* Working to define the biology of enteropathy-associated T-cell lymphoma and target with novel agents.

### Local Invited Presentations

*No presentations below were sponsored by outside entities*

- 2005 Advanced Topics in Infectious Diseases / Lecture  
 MSKCC, New York, NY
- 2006-2007 Hematology/Oncology Fellow Conference / Lecture  
 MSKCC, New York, NY
- 2007 Infectious Disease Fellow Conference / Lecture  
 MSKCC, New York, NY
- 2007 Bone Marrow Transplant Service Nursing Conference / Lecture  
 MSKCC, New York, NY
- 2007 Human Oncology Pathogenesis Program / Seminar  
 MSKCC, New York, NY
- 2009 Lymphoma and Inflammatory Bowel Disease / Gastrointestinal Grand Rounds  
 Massachusetts General Hospital (MGH), Boston, MA
- 2009 Division of Hematology/Oncology Seminar Series / Lecture  
 Children's Boston Hospital (now Boston Children's Hospital [BCH]), Boston, MA

2009, 2011, 2016, 2018 Bone Marrow Transplant Grand Rounds / Lecture  
DFCI, Boston, MA

2009, 2011, 2015 Hematologic Oncology Visiting Committee / Invited Presentation  
DFCI, Boston, MA

2010, 2012, 2014 ALL Consortium Meeting / Invited Speaker  
DFCI, Boston, MA

2010 Functional Oncogenomics for NK/T-cell Neoplasms / Lecture  
Dana-Farber/Harvard Cancer Center (DF/HCC) Lymphoma/Myeloma Program Retreat,  
Boston, MA

2010 Pediatric Leukemia/Lymphoma Protocol Conference / Lecture  
DFCI/BCH, Boston, MA

2010 Program in Immunology Seminar Series / Lecture  
DF/HCC, Boston, MA

2010 Center for Inflammatory Bowel Disease Seminar / Lecture  
BCH, Boston, MA

2011 Biostatistics and Computational Biology Seminar Series / Lecture  
DF/HCC, Boston, MA

2013 Hematologic Neoplasia Division Faculty Seminar Series / Lecture  
DFCI, Boston, MA

2013 Leukemia Retreat / Invited Speaker  
DF/HCC, Boston, MA

2013 Bone Marrow Transplant and Emergency Preparedness Conference / Lecture  
MGH, Boston, MA

2013 New Approaches to Cure Lymphoid Malignancies / Seminar  
Division of Hematology/Oncology Seminar Series, BCH, Boston, MA

2014 Defining Targeted Landscapes in Rare Hematologic Malignancies / Lecture  
Precision Cancer Medicine Symposium, Center for Cancer Genome Discovery, DFCI,  
Boston, MA

2014 Xenografting of Human Leukemias / Lecture  
Hematologic Malignancy Clinical Care Conference, DFCI/BCH, Boston, MA

2014 Targeting Multiple Pathways in Mantle Cell Lymphoma / Lecture  
Chronic Lymphocytic Leukemia (CLL)-Lymphoma Workshop, DFCI, Boston, MA

- 2014 Patient-derived Xenograft (PDX) Models to Interrogate and Target Leukemias and Lymphomas / Lecture  
Cancer Biology Meeting, Broad Institute, Cambridge, MA
- 2014, 2017 The Weinstock Laboratory / Speaker  
Pediatric/Oncology Faculty Data Blitz, BCH, Boston, MA
- 2015 A JAK2 Inhibitor that Inhibits JAK2 / Lecture  
Leukemia Research Conference, DF/HCC, Boston, MA
- 2015 PRoXe: A Xenograft Resource of Hematologic Malignancies / Lecture  
Division of Hematologic Neoplasia Seminar Series, DFCI, Boston, MA
- 2015 Defining Therapeutic Sensitivity in Single Cancer Cells / Seminar  
DFCI/Koch Institute Bridge Project Seminar, Boston, MA
- 2015 Co-developing PDX Models / Lecture  
DFCI/Novartis Drug Discovery Program, Cambridge, MA
- 2015 Curing Lymphoid Malignancies: of Mice and (Wo)men / Grand Rounds  
MGH Cancer Center, Boston, MA
- 2015 Inducing Non-Cell Autonomous Killing to Overcome Drug Resistance in Double-hit Lymphoma / Lecture  
DFCI/Koch Institute Bridge Project Selection Committee, Boston, MA
- 2016 Assaying Therapeutic Sensitivity Based on Cell Mass Kinetics / Lecture  
Cell Circuits and Epigenomics Seminar Series, Broad Institute, Cambridge, MA
- 2016 Measurements of Cell Mass to Define Therapeutic Response Heterogeneity / Lecture  
DFCI/Novartis Heterogeneity and Metastasis Cluster, DFCI, Boston, MA
- 2016 Curing Lymphoid Malignancies: Any Way We Can / Lecture  
Dana-Farber/Novartis Drug Discovery Program, DFCI, Boston, MA
- 2016 Curing Lymphoid Malignancies: Of Mice and Kids / Grands Rounds  
Hematology/Oncology Grand Rounds, BCH, Boston, MA
- 2016 Targeting PI3 Kinase in PTCL / Lecture  
T-cell Lymphoma SCOR Annual Review, DFCI, Boston, MA
- 2016 T cell Lymphomas: The Horrible and the Miserable /Lecture  
DFCI/Novartis Drug Discovery Program, Novartis Institute for Biomedical Research, Cambridge, MA
- 2016 Targeting JAK2 with Type II Inhibitors / Lecture  
Lunch and Learn Series, Cell Press and American Cancer Society, Cambridge, MA
- 2017 Public Repository of Xenografts / Invited Speaker

Solid Tumor Research Retreat, Department of Pediatric Oncology, DFCI, Boston, MA

- 2017 Turning Responses into Cures / Invited Speaker  
Trustees Science Committee, DFCI, Boston, MA
- 2017 Suspended Microchannel Resonators for Assaying Minimal Residual Disease (MRD) /  
Invited Speaker  
Leadership Meeting, DF/HCC, Boston, MA
- 2017 Targeting Peripheral T-cell Lymphomas / Invited Speaker  
Cancer Biology Meeting, Broad Institute, Cambridge, MA
- 2017 Can Smarter Models Help Cure Cancer / Invited Speaker  
Medical Exchange Club, Boston, MA
- 2017 Is it Possible to Model Cure of ALL? / Invited Speaker  
Dana-Farber Pediatric Leukemia Network Meeting, Boston, MA
- 2017 T-cell Lymphomas / Speaker  
DF/HCC SPORE Leadership Review, Boston, MA
- 2017 Deciphering Microenvironmental Interactions in PDX Models: A Worthwhile Endeavor?  
/Invited Speaker  
Division of Hematologic Neoplasia Investigator Meeting, DFCI, Boston, MA
- 2017 Using patient-derived models to define therapeutic vulnerabilities in lymphoid  
neoplasms/Invited Speaker  
Postgraduate Association Brain Lunch, DFCI, Boston, MA
- 2017 Strategies for Mitigating Radiation Response / Invited Speaker  
Radiation Oncology Research Showcase, DFCI, Boston, MA
- 2018 Forum on Patient-Derived Models: What's Next / Invited Speaker  
Hematologic Neoplasia and Immunologic Therapies Seminar, DFCI, Boston, MA
- 2018 Probing cell-extrinsic response by single-cell RNA sequencing (scRNA-Seq) / Session  
Chair  
MIT/DFCI Centers for Cancer Systems Biology, Koch Institute, Boston, MA
- 2018 Targeting vulnerabilities in lymphoid neoplasms / Invited Lecture  
AstraZeneca Hematologic Malignancies Symposium, Waltham, MA
- 2018 Targeting vulnerabilities in lymphoid neoplasms / Invited Lecture  
Department of Pathology and Laboratory Medicine Grand Rounds  
Boston University Medical Center, Boston, MA
- 2019 Targeting vulnerabilities in lymphoid neoplasms / Invited Lecture  
Clinical Pathology Division Conference, BWH, Boston, MA

- 2019 Targeting vulnerabilities in lymphoid neoplasms / Invited Lecture  
Department of Pathology Seminar, BCH, Boston, MA
- 2019 Multiparametric approaches to target terrible lymphomas / Seminar  
Disease Atlas Meeting, Laboratory for Systems Pharmacology, HMS, Boston, MA
- 2019 Novel diagnostics for lymphoma in 2019 and beyond / Invited presentation  
Lymphoma Program Meeting, DFCI, Boston, MA
- 2019 T-cell lymphomas: Advances in Genomics and Classification / Invited presentation  
Hematology Leadership Workshop, HMS, Boston, MA
- 2019 Targeting terrible lymphomas / Invited presentation  
Hematology/Oncology Grand Rounds, BCH, Boston, MA
- 2019 Advances in T-cell lymphoma biology / Invited presentation  
Pathology Grand Rounds, MGH, Boston, MA
- 2020 Novel technologies for detecting and targeting MRD / Invited presentation  
Breast Cancer Service Retreat, DFCI, Boston, MA
- 2020 Inexpensive diagnostics to transform cancer care / Invited presentation  
Cancer Biology Meeting, Broad Institute, Cambridge, MA
- 2020 New approaches for lymphoid malignancies / Invited presentation  
Independent Investigators Meeting, DFCI, Boston, MA
- 2020 T-cell lymphoma: Trials, Tribulations and Triumphs(?) / Invited presentation  
Medical Oncology Grand Rounds, DFCI, Boston, MA
- 2020 Diagnostic strategies for lymphoma and other diseases of one / Invited presentation  
Liquid Biopsy and Cancer Diagnostics Lecture Series, Broad Institute, Cambridge, MA
- 2021 Defining novel vulnerabilities in lymphoid malignancies / Invited Lecture  
VOR Biopharma, Cambridge, MA
- 2021 Molecular Diagnostics for T-cell Lymphoma / Invited Lecture  
Molecular Diagnostics: Current Roles in Cancer Diagnosis and Patient Management  
Harvard Medical School, Boston, MA

### **Report of Regional, National and International Invited Teaching and Presentations**

#### **[Invited Presentations and Courses](#)**

##### Regional

*Those presentations below sponsored by outside entities are so noted and the sponsor is identified.*

- 2005 Infectious Disease Fellow Conference / Lecture  
New York University Medical Center, New York, NY



- 2005 Infections in BMT Recipients / Grand Rounds  
Department of Medicine, St. Joseph's Hospital, Paterson, NJ (Pfizer, Inc.)
- 2005 New Agents to Treat Fungal Infections / Grand Rounds  
Division of Infectious Disease, State University of New York, Stony Brook, Stony Brook, NY (Pfizer, Inc.)
- 2006 New Agents to Treat Fungal Infections / Grand Rounds  
Division of Hematology/Oncology, North Shore University Hospital, Manhasset, NY (Pfizer, Inc.)
- 2006 New Agents to Treat Fungal Infections / Grand Rounds  
Division of Pulmonary Medicine, Long Island College Hospital, Queens, NY (Pfizer, Inc.)
- 2006 New Agents to Treat Fungal Infections / Grand Rounds  
Department of Medicine, Brooklyn Hospital, Brooklyn, NY (Pfizer, Inc.)
- 2006 New Agents to Treat Fungal Infections / Grand Rounds  
Division of Pulmonary and Critical Care Medicine, State University of New York, Brooklyn, NY (Pfizer, Inc.)
- 2006 New Agents to Treat Fungal Infections / Grand Rounds  
Division of Infectious Diseases, Beth Israel Medical Center, New York, NY (Pfizer, Inc.)
- 2006 New Agents to Treat Fungal Infections / Grand Rounds  
Department of Medicine, Woodhull Medical Center, Brooklyn, NY (Pfizer, Inc.)
- 2006 Infectious Disease Fellow Conference / Lecture  
New York University Medical Center, New York, NY
- 2007 New Agents to Treat Fungal Infections / Grand Rounds  
Department of Medicine, White Memorial Hospital, New York, NY (Schering-Plough, Inc.)
- 2007 New Agents to Treat Fungal Infections / Grand Rounds  
Department of Medicine, St. John's Medical Center, Queens, NY (Schering-Plough, Inc.)
- 2007 Assaying Double-strand Break (DSB) Repair with Targeted Nucleases / Invited Seminar  
Division of Hematology/Oncology, Columbia University, New York, NY
- 2010 Infection and Malignancy in Patients with Inflammatory Bowel Disease (IBD) Lecture  
IBD: Art and Science in the Diagnosis and Treatment Conference, Boston, MA
- 2011 Functional Oncogenomics / Invited Seminar  
Nature Biotechnology SciCafe, Boston, MA
- 2011, 2012 Basics of Leukemia / Invited Seminar

Cancer Biology Course, Novartis Institute for Biomedical Research, Cambridge, MA  
(Novartis, Inc.)

- 2013 Supporting Hematopoietic Reconstitution after Radiation Disasters: The Role of the Cancer Center / Invited Lecture, Dr. Joseph R. and Nancy Bove Transfusion Medicine Visiting Professorship  
Yale University School of Medicine, New Haven, CT
- 2015 Curing Hematologic Malignancies: In Mice Then Men? / Invited Lecture  
Jackson Laboratories, Farmington, CT
- 2015 Targeting the Diversity of B-ALL through Preclinical Phase II-like Trials / Invited Speaker  
DF/Novartis Retreat, Stowe, VT
- 2016 Targeting Lymphoid Malignancies in Mice and Man / Invited Seminar  
Eastern Maine Medical Center, Bangor, ME
- 2017 Targeting T Cell Lymphomas with PI3 Kinase / Invited Seminar  
Verastem Seminar Series, Needham, MA (Verastem, Inc.)
- 2017 PDX capabilities for single-cell analysis of drug response / Lightning Talk  
Cancer Systems Biology Consortium Annual Meeting, NCI and Broad Institute, Cambridge, MA
- 2017 Novel therapeutic approaches for AML and other hematologic malignancies / Invited Seminar  
Dragonfly Therapeutics, Waltham, MA (Dragonfly, Inc.)
- 2017 Translational Discovery in T-cell Lymphomas: Review  
LLS Specialized Center of Research Annual Review, New York, NY
- 2017 Targeting lymphoid malignancies in adults and children / Grand Rounds  
Pediatric Grand Rounds, MSKCC, New York, NY
- 2018 Targeting vulnerabilities in high-risk lymphoid neoplasms / Invited Lecture  
Novel Perspectives and Emerging Trends in the Treatment of Hematologic Neoplasms  
Mini-symposium, Waltham, MA (Astra Zeneca, Inc.)
- 2019 What can we learn from rare variants of follicular lymphoma? / Invited Lecture  
4<sup>th</sup> MSKCC Lymphoma Symposium, MSKCC, New York, NY
- 2019 Defining vulnerabilities and new targets in peripheral T-cell lymphomas / Invited Presentation  
International Workshop on Non-Hodgkin's Lymphoma, Cambridge, MA
- 2020 Defining precursors in low-grade lymphomas that seed second lymphomas / Invited Presentation  
Second AACR International Meeting: Advances in Malignant Lymphoma, Cambridge, MA (by Zoom)

- 2021 New approaches for high-risk lymphoid malignancies / Invited Lecture  
Columbia University Irving Medical Center Hematology/Oncology Grand Rounds, New York, NY (by Zoom)
- 2021 New targets in T-cell lymphomas / Keynote Lecture  
6<sup>th</sup> MSKCC Lymphoma Symposium, MSKCC, New York, NY
- 2021 New strategies to cure incurable cancers/ Ralph Nachman Visiting Professorship  
Joan and Sanford Weil Department of Medicine, WCMC, New York, NY

National

*Those presentations below sponsored by outside entities are so noted and the sponsors are identified.*

- 2004 Infections in Bone Marrow Transplant (BMT) Recipients / Lecture  
Focus on Hospital Associated Infections Conference, Miami, FL
- 2004 Infections in BMT Recipient / Grand Rounds  
Johns Hopkins University Cancer Center, Baltimore, MD
- 2006 Fungal Infections in BMT Recipients / BMT Grand Rounds  
H. Lee Moffitt Cancer Center, Tampa, FL (Schering-Plough, Inc.)
- 2007 Assaying Double-strand Break (DSB) Repair with Targeted Endonucleases / Invited Speaker  
Cancer Biology Conference, Northwestern University Medical Center, Chicago, IL
- 2007 Assaying DSB Repair with Targeted Endonucleases / Invited Speaker  
Hematologic Neoplasia Conference, DFCI, Boston, MA
- 2007 New Agents to Treat Fungal Infections / Grand Rounds  
Division of Hematology/Oncology, University of California, Irvine, CA (Schering-Plough, Inc.)
- 2007 New Agents to Treat Fungal Infections / Grand Rounds  
Hematology/Oncology Seminar, Los Angeles Children's Hospital, Los Angeles, CA (Schering-Plough, Inc.)
- 2007 Medical and Organizational Challenges Resulting from a Nuclear Emergency / Invited Speaker  
Radiation Injury Treatment Network, Bethesda, MD
- 2007 New Agents to Treat Fungal Infections / Grand Rounds  
Texas Children's Hospital, Dallas, TX
- 2009 Epstein-Barr Virus and Lymphoma in Immune Suppressed Patients/Educational Session  
Digestive Diseases Week, Chicago, IL

- 2009, 2011 Nuclear Terrorism: Preparedness and Response for Hematology/Oncology Centers /  
Invited Speaker  
Radiation Injury Treatment Network, Bethesda, MD
- 2010 Functional Oncogene Identification in Lymphoid Neoplasms / Conference Lecture  
T-Cell Lymphoma Forum, Maui, HI
- 2010 Keys to IBD 2010: Treatment, Diagnosis and Pathophysiology / Invited Speaker  
Falk Symposium, Miami, FL
- 2010 Navigating the Physician Scientist Pathway / Session Chair and Panelist  
AACR Research Meeting, Washington, DC
- 2011 Management of Acute Radiation Syndrome (ARS) after a Nuclear Detonation / Invited  
Speaker  
Medical Countermeasures Conference Series, US Food and Drug Administration, Silver  
Spring, MD
- 2011 Management of Acute Radiation Syndrome (ARS) after a Nuclear Detonation / Invited  
Speaker  
Conference Lecture, Centers for Disease Control, Atlanta, GA
- 2011 Nuclear Terrorism: Preparedness and Response for Hematology/Oncology Centers /  
Invited Speaker  
Radiation Injury Treatment Network, Chicago, IL
- 2011 Management of ARS after a Nuclear Detonation / Panelist  
Center for Biosecurity of the University of Pittsburgh, Washington, DC
- 2011 The Radiation Injury Treatment Network / Conference Lecture  
Annual Meeting of the National Association for Radiologic Readiness, Arlington, VA
- 2012 National Burn Bed Strategy Conference / Invited Speaker  
Office of Preparedness and Emergency Operations, DHHS, Atlanta, GA
- 2012 Innovation in Cancer Research / Invited Speaker  
Cancer Community at Illinois Symposium, Champaign, IL
- 2012 Hematology/Oncology Grand Rounds / Invited Speaker  
Weill Cornell Medical College, New York, NY
- 2012 Oncology Grand Rounds / Invited Speaker  
Bozeman Deaconess Hospital, Bozeman, MT
- 2012 Research Affinity Group Lecture Series / Invited Speaker  
Children's Hospital of Philadelphia, Philadelphia, PA
- 2012 Blood Products Mini-Symposium / Invited Speaker  
Department of Health and Human Services, Bethesda, MD

- 2013 Nationwide Response Issues After an Improvised Nuclear Device Attack / Invited Speaker  
Institute of Medicine, Washington, DC
- 2013 Public Health Radiation Initiatives – Updates from the Field / Invited Speaker  
National Association of County and City Health Officials Annual Meeting, Dallas, TX
- 2013 University of Chicago Cancer Center Seminar Series / Invited Lecture  
University of Chicago, Chicago, IL
- 2013 Mitigation and Treatment of Radiation Injury / Invited Lecture  
Centers for Medical Countermeasures and Radiation Injury Treatment Network,  
Baltimore, MD
- 2013 Combination Strategies to Cure Lymphoid Leukemias / Invited Lecture  
Dana-Farber/Novartis Drug Discovery Program Retreat, Pasadena, CA
- 2013 Targeting HSP90 in B-cell Acute Lymphoblastic Leukemia / Invited Lecture  
William Lawrence and Blanche Hughes Foundation Annual Meeting, Westlake, CA
- 2013 Combination Strategies to Cure Lymphoid Leukemias / Invited Lecture  
Sylvester Cancer Center, University of Miami Medical Center, Miami, FL
- 2013 Epigenetic Alterations in Hematologic Malignancies Session / Invited Lecture  
Federation of American Societies for Experimental Biology (FASEB) Meeting on  
Hematologic Malignancies, Saxtons River, VT
- 2014 New Strategies to Cure Lymphoid Malignancies / Dean's Lecture, Invited Lecture  
Weill Cornell Medical College, New York, NY
- 2014 Human Oncology Pathogenesis Program Lecture / Invited Speaker  
Memorial Sloan-Kettering Cancer Center, New York, NY
- 2014 Meet-the-Expert Session / Participant  
AACR National Meeting, San Diego, CA
- 2014 Meeting on Lymphoma Biology / Invited Speaker  
American Society of Hematology, Colorado Springs, CO
- 2014 Targeting JAK2 in Acute Lymphoblastic Leukemia / Invited Speaker  
William Lawrence and Blanche Hughes Foundation Retreat, Lexington, KY
- 2015 Curing Hematologic Malignancies: In Mice Then Men? / Invited Lecture  
University of Nebraska Medical Center, Omaha, NE
- 2015 How to Best Engage RITN Staff to be Prepared / Invited Speaker  
Medical and Organizational Challenges Resulting from a Radiation/Nuclear Emergency,  
RITN Conference, Rockville, MD

- 2015 Curing Hematologic Malignancies: In Mice Then Men? / Invited Lecture  
Individualizing Medicine Conference 2015, Mayo Clinic, Rochester, MN
- 2015 Updates from the Weinstock Lab / Invited Lecture  
Hematology Conference, Mayo Clinic, Rochester, MN
- 2015 Curing Hematologic Malignancies: In Mice then (Wo)Men? / Grand Rounds  
Cancer Center, City of Hope, Duarte, CA
- 2015 RITN: Healthcare Professionals Preparing for a Mass Casualty Radiological Event /  
Invited Speaker  
EPR BioDose 2015, Hanover, NH
- 2015 Phase II-like Trials *in muribus*: Overcoming the Drug Development Bottleneck / Invited  
Speaker  
William Lawrence and Blanche Hughes Foundation Retreat, Westlake Village, CA
- 2015 Historical Patient Medical Management of Radiation Injury / Invited Lecture  
NIAID/FDA Medical Management Forum, Silver Spring, MD
- 2015 Mentor Lecture for Abner Louissaint, MD, PhD / Lecture  
Harold Amos Medical Faculty Development Program Annual Meeting, Dallas, TX
- 2015 Translational Discovery at the Interface of Lymphoid Transformation and DNA Repair /  
Invited Speaker  
Winthrop Rockefeller Cancer Center, University of Arkansas, Little Rock, AR
- 2016 Translational Discovery in Lymphoma / Invited Speaker  
Moffitt Cancer Center, Tampa, FL
- 2016 Added Value of Patient-Derived Xenografts for Cancer Research and Their Role in  
Guiding Clinical Treatment / Invited Speaker  
AACR National Meeting, New Orleans, LA
- 2016 Defining the Vulnerabilities of Peripheral T-Cell Lymphoma / Invited Speaker  
ASH Meeting on Lymphoma Biology, Colorado Springs, CO
- 2016 Lymphoma Roadmap: Where Are We Now / Invited Speaker  
ASH Meeting on Lymphoma Biology, Colorado Springs, CO
- 2016 New Targets in Peripheral T-Cell Lymphomas / Invited Speaker  
Lymphomas and Myeloma 2016, New York, NY
- 2016 Models of T Cell Lymphoma to Advance Therapeutics / Keynote Lecture  
Lymphoma Retreat, Cornell University, New York, NY
- 2016 New Developments in T Cell Lymphoma Biology and Translational Research / Invited  
Speaker

- Lymphoma Committee Meeting, Alliance for Clinical Trials in Oncology, Chicago, IL
- 2016 Curing Cancer with Sex, Drugs and Money / Invited Speaker  
Frederick National Laboratory for Cancer Research, Frederick, MD
- 2016 Targeting Minimal Residual Disease in Acute Leukemias / Invited Speaker  
Commonwealth Fund Meeting, MSKCC, New York, NY
- 2017 Targeting Lymphomas with Sex, Drugs and Money / Grand Rounds  
Division of Hematology/Oncology, MSKCC, New York, NY
- 2017 Curing Lymphoid Malignancies: Of Mice and Men / Grand Rounds  
Emil J. Freireich Leukemia Hematology Grand Rounds, University of Texas MD  
Anderson Cancer Center, Houston, TX
- 2017 Preclinical Models for Lymphoma Therapeutics Development / Invited Speaker  
Lymphoma Expert Forum, Dallas, TX
- 2017 Functional Assays to Select Therapeutics in Leukemia / Invited Speaker  
FASEB Meeting on Hematologic Malignancies, Saxtons River, VT
- 2017 Curing Lymphoid Malignancies: Of Mice and Men / Grand Rounds  
Division of Hematology/Oncology, Northwestern University Medical Center, Chicago, IL
- 2017 The emerging role of the patient in an evolving health ecosystem / Invited Panelist  
DIA Metrics in Patient-Centered Drug Development Conference, Rockville, MD
- 2017 New approaches for targeting T-cell lymphomas / Invited Lecture  
Leukemia and Lymphoma Society Medicine/Science Committee Meeting, Atlanta, GA
- 2017 Assaying MRD with functional measurements of mass kinetics / Invited Lecture  
Biomarkers Consortium (BC) Cancer Steering Committee (CSC) in-person meeting  
Foundation for the National Institutes of Health (FNIH), Bethesda, MD
- 2017 Targeting vulnerabilities in lymphoid neoplasms / Invited Lecture  
University of Chicago Ludwig Center, Chicago, IL
- 2017 Modeling Human Immunity and Disease / CellPress Webinar  
<http://view6.workcast.net/register?cpak=6477842955389592&referrer=webinarpage>
- 2018 What is the molecular basis and most promising road towards molecular targeted therapies  
for double-hit lymphoma? / Invited Lecture and Session Chair  
Inaugural AACR Meeting on Advances in Malignant Lymphoma: Maximizing the Basic-  
Translational Interface for Clinical Application, Boston, MA
- 2018 Translocation models for T-cell lymphoma / Invited Lecture  
Inaugural AACR Meeting on Advances in Malignant Lymphoma: Maximizing the Basic-  
Translational Interface for Clinical Application, Boston, MA

- 2018 Interrogating the xenograft microenvironment / Invited Lecture  
Advances in Patient-Derived Xenograft Modeling in Cancer Workshop  
AACR Annual Meeting, Chicago, IL
- 2018 Functional approaches to target lymphomas / Invited Lecture  
LRF Lymphoma Clinical Research Mentoring Program, Scottsdale, AZ
- 2018 Defining and targeting vulnerabilities in T cell lymphomas / Invited Lecture  
Thomas Jefferson Medical College, Philadelphia, PA
- 2018 Expert Stakeholder Panel on Innovative Financing / Invited Panelist  
Network for Excellence in Healthcare Innovation (NEHI), Washington, DC
- 2018 Genomics of T-cell lymphomas / Educational Session Lecture  
American Society of Hematology Annual meeting, San Diego, CA
- 2019 Defining novel vulnerabilities in lymphoid malignancies / Elkin Lecture  
Winship Cancer Center, Emory University, Atlanta, GA
- 2019 Minding the gaps in medical preparedness for a Rad/Nuke Incident / Invited Panelist  
Radiation Injury Treatment Network Annual Meeting, Crystal City, VA
- 2019 Developing precision diagnostics in lower- and middle-income countries / Invited Speaker  
International Consortium on Acute Leukemia Meeting (ICAL), Orlando, FL
- 2020 Defining novel vulnerabilities in lymphoid malignancies / Oncology Grand Rounds  
Baylor University, Houston, TX
- 2020 New Strategies to Improve Outcomes from Lymphoid Malignancies / Invited Lecture  
St. Jude's Children's Research Hospital, Memphis, TN
- 2020 Defining novel vulnerabilities in lymphoid malignancies / Cancer Center Grand Rounds  
George Washington University, Washington, DC
- 2020 Defining novel vulnerabilities in lymphoid malignancies / Jonas Lymphoma Lectureship  
Washington University of St. Louis, St. Louis, MO
- 2021 Defining novel vulnerabilities in lymphoid malignancies / Center for Childhood Cancer  
Research (CCCR) Seminar Series, Children's Hospital of Philadelphia, Philadelphia, PA
- 2021 Transcriptional diagnostics for pediatric cancers in LMICs / Invited Lecture  
Global Pediatric Medicine, St. Jude's Children's Research Hospital, Memphis, TN

#### International

*Those presentations below sponsored by outside entities are so noted and the sponsors are identified.*

- 2008 US Response to Mass Casualty Radiation Events / Invited lecture  
12<sup>th</sup> World Health Organization Radiation Emergency Medical Preparedness and Assistance  
Network (REMPAN) meeting, Buenos Aires, Argentina



- 2008 Lymphoma and Inflammatory Bowel Disease / Truelove Plenary Lecture  
International Organization for the Study of Inflammatory Bowel Diseases, Kyoto, Japan
- 2008 Assaying DSB Repair with Targeted Endonucleases / Invited Seminar  
Department of Genetics, Kobe University, Kobe, Japan
- 2009 US Response to Mass Casualty Radiation Events / Invited Lecture  
World Health Organization (WHO) Meeting for Harmonization of Response to Radiation Events, Geneva, Switzerland
- 2009 Chromosomal Translocations: From Basic Models to Clinical Discovery / Invited Lecture  
Tel Aviv University, Sheba Medical Center, Tel Aviv, Israel
- 2011 Autologous Stem Cell Harvesting for Nuclear Power Plant Workers / Invited Lecture  
Controversies in Stem Cell Transplantation, Berlin, Germany
- 2013 Down Syndrome and the ALL Epigenome / Invited Lecture  
Acute Leukemia XIV: Biology and Treatment Strategies, Munich, Germany
- 2014 Mutations of G $\beta$  Subunits Confer Transformed and Resistance Phenotypes / Invited Lecture  
Dana-Farber/Novartis Drug Discovery Program Retreat, Lisbon, Portugal
- 2015 Type II JAK2 Inhibition in Acute Lymphoblastic Leukemia / Invited lecture  
Acute Leukemias XV: Biology and Treatment Strategies, Munich, Germany
- 2015 Targeting Cure in Leukemias using Patient-derived Xenografts / Invited Lecture  
Novartis Institute for Biomedical Research, Basel, Switzerland
- 2015 Innovative Strategies to Treat Viral Hepatitis in Lower- and Middle-income Countries /  
Invited Speaker  
Viral Hepatitis Prevention Board, London, England
- 2015 A Targetable Mediator of Chromosomal Translocations / Invited Lecture  
Meeting of the European Hematology Association, Vienna, Austria
- 2016 Novel Mechanisms of Epigenetic Dysregulation in B Cell Leukemias / Invited Speaker  
2<sup>nd</sup> International Conference on New Concepts in B-Cell Malignancies, European School of Hematology, Estoril, Portugal
- 2016 The ASH Roadmap for Lymphoma Biology / Invited Speaker  
2<sup>nd</sup> International Conference on New Concepts in B-Cell Malignancies, European School of Hematology, Estoril, Portugal
- 2017 New Strategies to Target Lymphoid Malignancies / Invited Lecture  
Bart's Cancer Institute Seminar Series, Bart's Cancer Institute, London, England
- 2017 New Financial Approaches to Support Access to Curative Therapeutics / Invited Speaker  
Fondazione the Bridge, Baveno, Italy

- 2017 Lymphoma Models to Assess Preclinical Therapeutics / Invited Speaker  
2<sup>nd</sup> International Dotan Symposium, Tel Aviv University, Tel Aviv, Israel
- 2018 New Strategies for Cancer Translation / Invited Speaker  
Center Hospitalier Universitaire de Rennes, Rennes, France
- 2018 The Public Repository of Xenografts / Grand Rounds  
University of Copenhagen, Copenhagen, Denmark
- 2018 Defining Vulnerabilities of PTCL / Invited Lecture  
T-Cell Lymphomas: we are close to the finalization, Bologna, Italy
- 2018 Future collaboration with CTCL / Invited Presentation  
Cutaneous Lymphoma International Consortium Investigator Meeting St. Gallen,  
Switzerland
- 2018 Co-Clinical Trials with PDX models / Invited Lecture  
Basic Science-in-Focus, European Hematology Association Meeting, Stockholm, Sweden
- 2018 How to predict responses *in silico* and *in vitro*? / Invited Lecture and Session Chair  
4<sup>th</sup> International Conference on New Concepts in Lymphoid Malignancies: Focus on  
Aggressive Lymphoma. European School of Hematology, Saggart (Dublin), Ireland
- 2018 Approaches to advance precision medicine and immune-oncology in hematologic  
malignancies/ Invited Lecture  
Mundipharma EDO Annual Meeting, Seville, Spain (Mundipharma EDO GmbH)
- 2019 Defining novel vulnerabilities in T-cell lymphomas/Invited Lecture  
Japanese Society of Hematology Annual Meeting, Tokyo, Japan
- 2019 Lymphoma xenografts: how to get back to the bench/Invited Lecture and Session Co-Chair  
5<sup>th</sup> International Conference on New Concepts in Lymphoid Malignancies  
European School of Hematology, Estoril, Portugal
- 2019 Translational discovery in lymphoid neoplasms / Invited Lecture  
Department of Pathology Lecture, Kurume, Japan
- 2020 Identifying drug vulnerabilities through PDX models / Invited Lecture  
International Rare Cancers Initiative (IRCI) PTCL Group Meeting
- 2021 Human Xenograft Models of Leukemia and Lymphoma  
Transcription Factor Drug Development Virtual Summit, London, England
- 2021 T-cell lymphomas: vulnerabilities and therapeutic opportunities / Invited Lecture  
6<sup>th</sup> Conference of the LYSA (Lymphoma Study Association), Rennes, France
- 2021 Novel targets in T-cell lymphomas / Invited Lecture

International Scientific Symposium of the Collaborative Research Center, Munich, Germany

## **Report of Clinical Activities and Innovations**

### **Current Licensure and Certification**

2000-2008	Medical License, State of New York
2004-	Board Certified, Medical Oncology, American Board of Internal Medicine (ABIM)
2005-2015	Board Certified, Infectious Diseases, ABIM
2007-	Medical License, Commonwealth of Massachusetts

### **Practice Activities**

2005-2007	Inpatient Care	Adult Blood and Marrow Transplantation and Infectious Diseases Services, MSKCC	8 weeks per year
2010-	Inpatient/Outpatient Care	Medical Oncology, Adult Blood and Marrow Transplantation Services, DFCI Inpatient Hospital and Outpatient BMT Program	2-4 weeks per year

### **Clinical Innovations**

Guidelines for Mass Casualty Radiation Events, 2010-2016

Developed and updated treatment guidelines and template admission orders for casualties affected by a mass radiation incident, such as an improvised nuclear device. These include:

- 1) Radiation Event Medical Management Website Template Order Set, developed in collaboration with Judy Bader, M.D., in the National Library of Medicine. These are a national resource and available at: <http://www.remm.nlm.gov/adultorderform.htm>.
- 2) Grand Rounds Presentation, "Medical Response to Radiation Exposure: The Role of Hematologists", developed in collaboration with the Radiation Injury Treatment Network and National Marrow Donor Program. This presentation is intended for use as an educational tool at medical centers that may be involved in the response to a radiological accident or terrorist event and has been utilized by practitioners across the nation. Available at: <http://www.nmdp.org/RITN/REFERENCE/index.html>.
- 3) Acute Radiation Syndrome treatment guidelines for the Radiation Injury Treatment Network. Available at: <http://www.ritn.net/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=2147483696&libID=2147483696>.

- 4) Data entry forms from the National Marrow Donor Program. These are a national resource for centers that care for casualties after a radiological event.

BWH Night Float  
Training Curriculum,  
2012, 2018

Contributed to case-based Brigham and Women's Medicine Residency Curriculum for Night Float (NF) training by co-developing a presentation on neutropenic fever. Available on the Brigopedia NF Curriculum page at: [https://brigopedia.partners.org/index.php/Night\\_Float\\_Curriculum](https://brigopedia.partners.org/index.php/Night_Float_Curriculum).

### Report of Technological and Other Scientific Innovations

CRLF2 in Precursor B-  
Cell Acute  
Lymphoblastic Leukemia

US patent application number 13/508395, filed November 24, 2010, patent US 2012/0282258A1, issued November 8, 2012; WIPO patent application number, PCT/US2010/057942, filed November 24, 2010; patent WO/2011/066344A1, issued June 3, 2011.

The invention relates to cytokine receptor-like factor 2 (CRLF2), and particularly certain mutant forms of CRLF2 as prognostic and therapeutic targets in precursor B-cell acute lymphoblastic leukemia (B-ALL). Mutant CRLF2 with a Phe232Cys (F232C) mutation is overexpressed and constitutively activates STAT5 in a subset of B-ALL patients with particularly poor prognosis. Methods and compositions useful for identifying, inhibiting expression, and inhibiting activity of the mutant CRLF2 are provided. Also provided are methods and compositions useful for treating B-ALL.

Compositions and  
Methods for  
Identification,  
Assessment, Prevention  
and Treatment of Cancer  
Using Histone  
H3K27ME3 Biomarkers  
and Modulators

World International Property Organization (WIPO) patent application number PCT/US2014/038938, publication number WO/2014/190035, filed May 21, 2014.

The present invention relates to methods for identifying, assessing, preventing, and treating cancer (*e.g.*, lymphoid and/or myeloid malignancies in humans). A variety of histone H3K27me3 biomarkers are provided, wherein alterations in the copy number of one or more of the biomarkers and/or alterations in the amount, structure, and/or activity of one or more of the biomarkers is associated with cancer status and indicates amenability to treatment or prevention by modulating H3K27me3 levels. The present invention further relates to methods of increasing the number of lymphoid progenitor cells (*e.g.*, increase self-renewal and cell proliferation) by contacting the lymphoid progenitor cells (*e.g.*, wild type and/or genomically altered cells) with an agent that inhibits polycomb repressor complex 2 (PRC2) activity or reduces H3K27me3 levels.

Compositions and  
Methods for  
Identification,  
Assessment, Prevention,  
and Treatment of Cancer  
Using Histone

US patent application number 14/890720, filed 5/21/14; publication number US 2016/0194718A1, issued July 7, 2016.

The present invention relates to methods for identifying, assessing, preventing, and treating cancer (*e.g.*, lymphoid and/or myeloid malignancies). A variety of histone H3K27me3 biomarkers are provided, wherein alterations in the copy number of one or more of the biomarkers and/or alterations in the amount, structure, and/or activity of one or more of

H3K27ME3 Biomarkers and Modulators	the biomarkers is associated with cancer status and indicates amenability to treatment or prevention by modulating H3K27me3 levels. The present invention further relates to methods of increasing the number of lymphoid progenitor cells ( <i>e.g.</i> , increase self-renewal and cell proliferation) by contacting the lymphoid progenitor cells ( <i>e.g.</i> , wild type and/or genomically altered cells) with an agent that inhibits polycomb repressor complex 2 (PRC2) activity or reduces H3K27me3 levels.
Treatment Methods for Minimal Residual Disease	US patent publication number 2020/0225239, filed: 1/10/20; publication date: July 16, 2020. Patient samples are monitored to detect minimal residual disease (MRD) post successful cancer treatment. Upon detection of MRD, functional assays can be performed on living cancer cells from the patient to evaluate possibly effective therapies along with subsequent genomic or other more destructive assays to provide additional efficacy information using a single sample. An effective treatment against the MRD can be identified and selected for the patient. The patient can be monitored and the process repeated until MRD can no longer be detected.
Co-Assays to Functional Cancer Biomarker Assays	US patent publication number 2020/0224279, filed: 1/10/20; publication date: July 16, 2020. The invention provides methods for evaluating disease, such as cancer, by way of performing multiple assays involving single-cell analysis on live cells isolated from a sample of a patient. The data obtained from the multiple assays is analyzed and linked to thereby provide a characterization of any given cell having undergone analysis, which, in turn, allows for evaluation of the sample either known to be, or suspected of being, cancerous. A report may be generated based on the data analysis, wherein the report provides information related to the cancer evaluation, including, but not limited to, whether the sample tested positive for cancer, a determination of a stage or progression of cancer, and a customized treatment plan tailored to an individual patient's cancer diagnosis.
Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof	US patent application number 19/060363, filed November 7, 2019, patent WO/2020/097400A1, issued May 14, 2020; patent WO/2011/097400A8, issued June 18, 2020. The present disclosure provides compounds of Formula (I') ( <i>e.g.</i> , compounds of Formula (I)), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, cocrystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided compounds may be kinase ( <i>e.g.</i> , Janus kinase (JAK), <i>e.g.</i> , Janus kinase 2 (JAK2)) inhibitors. Also provided are pharmaceutical compositions and kits including the provided compounds. Further provided are methods of using the provided compounds, pharmaceutical compositions, and kits ( <i>e.g.</i> , for treating a disease ( <i>e.g.</i> , proliferative disease) in a subject in need thereof).

Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof	<p>US patent application number 19/060358, filed November 7, 2019, patent WO/2020/097396A1, issued May 14, 2020.</p> <p>The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided compounds may be kinase (<i>e.g.</i>, Janus kinase (JAK), <i>e.g.</i>, Janus kinase 2 (JAK2)) inhibitors. Also provided are pharmaceutical compositions and kits including the provided compounds. Further provided are methods of using the provided compounds, pharmaceutical compositions, and kits (<i>e.g.</i>, for treating a disease (<i>e.g.</i>, proliferative disease) in a subject in need thereof).</p>
Rapid analysis of live cells	<p>US patent application number 16/739843, filed January 10, 2020, patent US/2020/0319162A1, issued October 8, 2020.</p> <p>The present disclosure provides methods and devices for rapidly measuring functional properties of living cells. Isolated living cells are obtained from tissue by a sample procedure such as fine needle aspiration. The cells are measured with minimal processing and no requirement of overnight culturing. Methods of the invention measure functional properties of living cells.</p>
Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof	<p>US patent application number 19/060360, filed November 7, 2019, patent WO/2020/097398A1, issued May 14, 2020.</p> <p>The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided compounds may be kinase (<i>e.g.</i>, Janus kinase (JAK), <i>e.g.</i>, Janus kinase 2 (JAK2)) inhibitors. Also provided are pharmaceutical compositions and kits including the provided compounds. Further provided are methods of using the provided compounds, pharmaceutical compositions, and kits (<i>e.g.</i>, for treating a disease (<i>e.g.</i>, proliferative disease) in a subject in need thereof).</p>
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia	<p>US patent application number 17/085,650, filed October 30, 2020, published May 6, 2021</p> <p>The present disclosure provides method of treating or preventing hematopoietic malignancy relapse in a subject in need thereof, comprising prognosing hematopoietic malignancy relapse in the subject in need thereof by determining an average cellular mass of the plurality of cells using the cellular mass of each individual cell of the plurality of cells, wherein an average cellular mass equal to or greater than a defined threshold indicates a low risk of hematopoietic malignancy relapse and an average cellular mass less than a defined threshold indicates a high risk of hematopoietic malignancy relapse; and administering, to a subject in need thereof of having a high risk of early onset hematopoietic malignancy relapse a therapeutically effective amount of one or more BCR-ABL tyrosine kinase inhibitors, pre-BCR signaling pathway inhibitors, p38 MAPK inhibitors or any combination thereof.</p>

## **Report of Education of Patients and Service to the Community**

### **Activities**

None of the presentations below were sponsored by outside entities.

- 2010                      Science and the Media / Moderator and Panelist  
WNYC National Public Radio Forum, New York, NY  
This forum involved scientists and members of the media to discuss how the advances and concerns can best be communicated.
- 2017                      6<sup>th</sup> Annual New England Walk of Life / Invited Speaker  
Armenian Bone Marrow Donor Registry, Waltham, MA  
This activity involved speaking to participants from the lay public who were participating in the Walk of Life about advances in bone marrow transplant treatment and research.
- 2017                      With/in/sight Public Outreach Series / Invited Speaker  
Koch Institute/MIT, Cambridge, MA  
This activity involved the presentation of novel discoveries made possibly by the Dana-Farber-Koch Institute Bridge Program to MIT alumni and members of the public.
- 2018                      Man & Woman of the Year Leadership Team  
Leukemia and Lymphoma Society, Massachusetts Chapter, Boston, MA  
This activity involved serving on a team of major donors, fundraisers, and members of the public to support fundraising for the Leukemia and Lymphoma Society.
- 2018                      The Pace of Progress Event / Invited Speaker  
Leukemia and Lymphoma Society, Massachusetts Chapter, Newton, MA  
This activity involved speaking to attendees from the lay public about efforts underway in the research and treatment of blood cancers.
- 2019                      Corporate Reception Breakfast / Invited Speaker  
Leukemia and Lymphoma Society, Massachusetts Chapter, Newton, MA  
This activity involved speaking to attendees from the lay public about efforts underway in the research and treatment of blood cancers.
- 2021                      Staff Vaccination Clinic / Volunteer Vaccinator  
DFCI, Boston, MA

### **Educational Material for Patients and the Lay Community**

Books, monographs, articles and presentations in media

1. Andrew Lo, **David Weinstock**. 'Health care loans' for Hep C Cure. Boston Globe. February 24, 2016.
2. Andrew Lo, **David Weinstock**. Developing more efficient financing methods for healthcare is a matter of life and death. Investment News, March 23, 2016.

### **Recognition**

2011                      Certificate of Appreciation                      Secretary of the Department of Health and Human Services

### **Report of Scholarship**

### **Peer-reviewed publications in print or other media**

#### **Research investigations**

1. **Weinstock DM**, Chang P, Aronson D, Kessler CM. Comparison of plasma prothrombin and factor VII and urine prothrombin F1 concentrations in patients on long-term warfarin therapy and those in the initial phase. *Am J Hematol* 1998;57:193-9.
2. **Weinstock DM**, Rogers M, Lim S, Eagan J, Sepkowitz KA. Seroconversion rates in health care workers using a latex agglutination assay after varicella virus vaccination. *Infect Control Hosp Epidemiol* 1999;20:504-7.
3. **Weinstock DM**, Merrick S, Malak SA, Jacobs J, Sepkowitz KA. Hepatitis C in an urban population infected with the Human Immunodeficiency Virus. *AIDS* 1999;13(18):2593-5.
4. **Weinstock DM**, Eagan J, Abdel Malak S, Kiehn TE, Wallace H, Sepkowitz KA. Control of influenza A on a bone marrow transplant unit. *Infect Control Hosp Epidemiol* 2000;21(11):730-2.
5. Rogers M, **Weinstock DM**, Eagan J, Kiehn T, Armstrong D, Sepkowitz KA. Rotavirus outbreak on a pediatric oncology floor: possible association with toys. *Am J Infect Control* 2000;28:378-80.
6. **Weinstock DM**, Hahn O, Wittkamp M, Khechinashvili G, Sepkowitz KA, Blumberg HM. Risk for tuberculosis infection among internally displaced persons in the Republic of Georgia. *Int J Tuberc Lung Dis* 2001;5:164-169.
7. Elvevag B, **Weinstock DM**, Akil M, Kleinman JE, Goldberg TE. A comparison of verbal fluency tasks in schizophrenic patients and normal controls. *Schizophr Res* 2001;51:119-26.
8. **Weinstock DM**, Rogers M, Eagan J, Abdel Malak S, Sepkowitz KA. Nosocomial central venous catheter infections among patients with different types of cancer. *Infect Control Hosp Epidemiol* 2002;23:234-5.



9. **Weinstock DM**, Feinstein MF, Sepkowitz KA, Jakubowski A. High rates of infection and colonization by nontuberculous mycobacteria after allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant* 2003;31:1015-21.
10. **Weinstock DM**, Boeckh M, Boulad F, Eagan JA, Fraser VJ, Henderson DK, Perl TM, Yokoe D, Sepkowitz KA. Post-exposure prophylaxis against VZV infection among hematopoietic stem cell transplant recipients: unanswered questions. *Infect Control Hosp Epidemiol* 2004;25:603-8.
11. **Weinstock DM**, Elliott B, Jasin M. A model of oncogenic rearrangements: differences between chromosomal translocations mechanisms and simple double-strand break repair. *Blood* 2006;107:777-80.
12. **Weinstock DM**, Jasin M. Alternative pathways for the repair of RAG-induced DNA breaks. *Mol Cell Biol* 2006;26:131-9.
13. **Weinstock DM**, Richardson CA, Elliott B, Jasin M. Modeling oncogenic translocations: distinct roles for double-strand break repair pathways in translocation formation in mammalian cells. *DNA Repair* 2006;5:1065-74.
14. **Weinstock DM**, Garces Ambrossi G, Brennan C, Kiehn T, Jakubowski A. Preemptive diagnosis and treatment of Epstein-Barr Virus-associated posttransplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. *Bone Marrow Transplant* 2006;37:539-46.
15. **Weinstock DM**, Conlon M, Iovino C, Aubrey T, Gudiol C, Riedel E, Young JW, Kiehn TE, Zuccotti G. Colonization, bloodstream infection and mortality caused by vancomycin-resistant *Enterococcus* early after allogeneic hematopoietic stem cell transplant. *Biol Blood Marrow Transplant* 2007;13:615.
16. Perales MA, Ishill N, Lomazow WA, **Weinstock DM**, Papadopoulos EB, Dastagir H, Chiu M, Boulad F, Castro-Malaspina HR, Heller G, Jakubowski AA, O'Reilly RJ, Small TN, Young JW, Kernan NA. Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease. *Bone Marrow Transplant* 2007;40:481.
17. **Weinstock DM**, Brunet E, Jasin M. Formation of NHEJ-derived reciprocal chromosomal translocations does not require Ku70. *Nat Cell Biol* 2007;9:978-81.
18. Jathavadem A, Feldman D, Ishill N, Turkula S, Patil S, Bosl GJ, Motzer RJ, **Weinstock DM**. Infectious complications from high dose chemotherapy for metastatic germ-cell tumors. *Biol Blood Marrow Trans* 2008;14:595-600.
19. **Weinstock DM**, Brunet E, Jasin M. Induction of chromosomal translocations in mouse and human cells using site-specific endonucleases. *J Nat Canc Inst Monog* 2008;39:20-4.
20. Chowdhury D, Xu X, Zhong X, Ahmed F, Zhong J, Liao J, Dykxhoorn DM, **Weinstock DM**, Pfeifer GP, Lieberman J. A PP4-phosphatase complex dephosphorylates gamma-H2AX generated during DNA replication. *Mol Cell* 2008;31:33-46.

21. Jathavadem A, Dure D, Taur Y, **Weinstock DM**. Limited utility of serum galactomannan assay after auto-SCT. *Bone Marrow Transplant* 2009;44:59-61.
22. D'Angelo S, Deutscher M, Dickler M, **Weinstock DM**. Hepatitis C Virus infection does not preclude standard breast cancer-directed therapy. *Clin Breast Cancer* 2009;9:51-2.
23. Kim JM, Parmar K, Huang M, **Weinstock DM**, Ruit CA, Kutok JL, D'Andrea AD. Inactivation of murine *Usp1* results in genomic instability and a Fanconi anemia phenotype. *Dev Cell* 2009;16:314-20.
24. Fernandes MS, Reddy MM, Gonneville JR, DeRoo SC, Podar K, Griffin JD, **Weinstock DM**, Sattler M. BCR-ABL promotes the frequency of mutagenic single strand annealing DNA repair. *Blood* 2009;114:1813-9.
25. Brunet E, Simsek D, Tomishima M, Gregory P, Urnov F, **Weinstock DM**, Jasin M. Chromosomal translocations induced at specific loci in human cells. *Proc Natl Acad Sci* 2009;106:10620-5.
26. Yoda A, Yoda Y, Chiaretti S, Bar-Natan M, Mani K, Rodig SJ, West N, Xiao Y, Brown JR, Mitsiades C, Sattler M, Kutok JL, DeAngelo DJ, Wadleigh M, Piciocchi A, Dal Cin P, Bradner JE, Griffin JD, Anderson KC, Stone RM, Ritz J, Foà R, Aster JC, Frank DA, **Weinstock DM**. Functional screening identified CRLF2 in precursor B-cell acute lymphoblastic leukemia. *Proc Natl Acad Sci* 2010;107:252-7.
27. Davids M, Case C, Hornung R, Chao NJ, Chute JP, Coleman CN, Weisdorf D, Confer DL, **Weinstock DM**. Assessing surge capacity for radiation victims with marrow toxicity. *Biol Blood Marrow Transplant* 2010;16:1436-41.
28. Wray J, Williamson EA, Chester S, Farrington J, Sterk R, **Weinstock DM**, Jasin M, Lee SH, Nickoloff JA, Hromas R. The transposase domain protein Metnase/SETMAR suppresses chromosomal translocations. *Cancer Genet Cytogenet* 2010;15:184-190.
29. Xu Y, Jiang X, Sun Y, Moskwa P, **Weinstock DM**, Price BD. The p400 ATPase regulates nucleosome stability and chromatin ubiquitination during DNA repair. *J Cell Biol* 2010;191:31-43.
30. Tsai A, Yoda A, **Weinstock DM\***, Lieber MR.  $t(X;14)(p22;q32) / t(Y;14)(p11;q32)$  CRLF2-IGH translocations from human B-lineage ALLs involve CpG-type breaks at CRLF2, but CRLF2/P2RY8 intrachromosomal deletions do not. *Blood* 2010;116:1993-4. \*corresponding author.
31. Moskwa P, Buffa FM, Pan Y, Panchakshari R, Gootipati P, Muschel RJ, Beech J, Kulshrestha R, Abdelmohsen K, **Weinstock DM**, Gorospe M, Harris AL, Helleday T, Chowdhury D. miR-182-mediated down-regulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. *Mol Cell* 2011;41:210-20.
32. Casagrande R, Wills N, Kramer E, Sumner L, Mussante M, Kurinsky R, McGhee P, Katz L, **Weinstock DM**, Coleman CN. Using the model of resource and time-based triage (MORTT) to guide scarce resource allocation in the aftermath of a nuclear detonation. *Disaster Medicine and Public Health Preparedness* 2011;5:S98-110.

33. Coleman CN<sup>^</sup>, **Weinstock DM<sup>^</sup>**, Casagrande R, Hick JL, Bader JL, Chang F, Nemhauser JB, Knebel AR. Triage and treatment tools for use in a scarce resources–crisis standards of care setting after a nuclear detonation. *Disaster Medicine and Public Health Preparedness* 2011;5:S111-21. <sup>^</sup>equal contribution
34. Fung H, **Weinstock DM**. Repair at single targeted DNA double-strand breaks in pluripotent and differentiated human cells. *PloS One* 2011;6:e20514.
35. Ward P, Cross J, Lu C, Weigert O, Abdel-Wahab O, Levine RL, **Weinstock DM**, Sharp KA, Thompson CB. Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production. *Oncogene* 2012;31:2491-8.
36. Weigert O, Kopp N, Lane AA, Yoda A, Dahlberg SE, Neuberg D, Bahar AY, Chapuy B, Kutok JL, Longtine JA, Kuo FC, Haley T, Salois M, Sullivan TJ, Fisher DC, Fox EA, Rodig SJ, Antin JH, **Weinstock DM**. Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation. *Cancer Discovery* 2012;2:47-55.  
Featured in Research Highlights (Cancer Biology): Sisterhood of Lymphoma. *Nature* 2011;480:417.
37. Weigert O, Lane AA, Bird L, Kopp N, Chapuy B, van Bodegom D, Toms AV, Marubayashi S, Christie AL, McKeown M, Paranal RM, Bradner JE, Yoda A, Gaul C, Vangrevelinghe E, Romanet V, Murakami M, Tiedt R, Ebel N, Evrot E, De Pover A, Régnier CH, Erdmann D, Hofmann F, Eck MJ, Sallan SE, Levine RL, Kung AL, Baffert F, Radimerski T, **Weinstock DM**. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. *J Exp Med* 2012;209:259-73.
38. Zhong J, Kim MS, Chaerkady R, Wu X, Huang TC, Getnet D, Mitchell CJ, Palapetta SM, Sharma J, O'Meally RN, Cole RN, Yoda A, Moritz A, Loriaux MM, Rush J, **Weinstock DM**, Tyner JW, Pandey A. TSLP signaling network revealed by SILAC-based phosphoproteomics. *Mol Cell Proteomics* 2012;11:M112.017764.
39. van Bodegom D, Zhong J, Dutta C, Kim M-S, Bird L, Weigert O, Tyner J, Pandey A, Yoda A, **Weinstock DM**. Differences in signaling through the B-cell leukemia oncoprotein CRLF2 in response to TSLP and through mutant JAK2. *Blood* 2012;120(14):2853-63.
40. Ott CJ, Kopp N, Bird L, Paranal RM, Qi J, Bowman T, Rodig SJ, Kung AL, Bradner JE<sup>^</sup>, **Weinstock DM<sup>^</sup>**. BET bromodomain inhibition targets both c-MYC and IL7R in high-risk acute lymphoblastic leukemia. *Blood* 2012;120(14):2843-52. <sup>^</sup>equal contribution
41. Shindoh N, Yoda A, Yoda Y, Sullivan TJ, Weigert O, Lane AA, Kopp N, Bird L, Rodig SJ, Fox EA, **Weinstock DM**. Next-generation cDNA screening for oncogene and resistance phenotypes. *PLoS One* 2012;7:e49201.
42. Dutta C, Day T, Kopp N, van Bodegom D, Davids MS, Ryan J, Bird L, Kommajosyula N, Weigert O, Yoda A, Fung H, Brown JR, Shapiro GI, Letai A, **Weinstock DM**. BCL2 suppresses PARP1 function and non-apoptotic cell death. *Cancer Res* 2012;72(16):4193-203.
43. Weigert O, **Weinstock DM**. The evolving contribution of hematopoietic progenitor cells to lymphomagenesis. *Blood* 2012; 120:2553-61.

44. Lane AA, Odejide O, Kopp N, Kim S, Yoda A, Erlich R, Wagle N, Abel GA, Rodig SJ, Antin JH, **Weinstock DM**. Low frequency clonal mutations recoverable by deep sequencing in patients with aplastic anemia. *Leukemia* 2013;27:968-71.
45. Wray J, Williamson EA, Singh SB, Wu Y, Cogle C, **Weinstock DM**, Zhang Y, Lee S-H, Zhao D, Shou L, Hauer-Jensen M, Pathak R, Klimek K, Nickoloff JA, Hromas R. PARP1 is Required for Chromosomal Translocations. *Blood* 2013;12:4359-65.
46. Wachter F, Grnert M, Blaj C, **Weinstock DM**, Jeremias I, Ehrhardt H. Impact of the p53 status of tumor cells on extrinsic and intrinsic apoptosis signaling. *Cell Commun Sig* 2013;11:27.
47. Montero J, Dutta C, van Bodegom D, **Weinstock DM**, Letai A. P53 regulates a non-apoptotic death induced by ROS. *Cell Death Diff* 2013;20:1465-7.
48. Kluk MJ, Ashworth T, Wang H, Knoechel B, Mason EF, Dorfman D, Pinkus G, Weigert O, Hornick JL, Chirieac LR, Hirsch M, Oh DJ, South AP, Leigh IM, Pourreyron C, Cassidy AJ, Deangelo DJ, **Weinstock DM**, Krop IE, Dillon D, Brock JE, Lazar AJ, Peto M, Cho RJ, Stoeck A, Haines BB, Sathayanayanan S, Rodig SJ, Aster JC. Gauging NOTCH1 activation in cancer using immunohistochemistry. *PloS One* 2013;8:e67306.
49. Park E, Kim JM, Primack B, **Weinstock DM**, Moreau LA, Parmar K, D'Andrea AD. Inactivation of Uaf1 causes defective homologous recombination and early embryonic lethality in mice. *Mol Cell Biol* 2013;33:4360-70.
50. Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N, Kim S, van Bodegom D, Bolla S, Teruya-Feldstein J, Hochberg, E, Louissaint A, Dorfman D, Stevenson K, Rodig SJ, Piccaluga PP, Jacobsen E, Pileri SA, Harris NL, Ferrero S, Inghirami G, Horwitz SM, **Weinstock DM**. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. *Blood* 2014;123:1293-6. Selected as the Plenary Paper for the February 27, 2014 issue of *Blood*.
51. Zhong J, Sharma J, Raju R, Palapetta SM, Prasad TS, Huang TC, Yoda A, Tyner JW, van Bodegom D, **Weinstock DM**, Ziegler SF, Pandey A. TSLP signaling pathway map: a platform for analysis of TSLP-mediated signaling. *Database (Oxford)* 2014(0):bau007.
52. Lane AA, Chapuy B, Lin CY, Tivey T, Li H, Townsend EC, van Bodegom D, Day TA, Wu S-C, Liu H, Yoda A, Alexe G, Schinzel AC, Sullivan TJ, Malinge S, Taylor JE, Stegmaier K, Jaffe JD, Bustin M, te Kronnie G, Izraeli S, Harris M, Stevenson KE, Neuberg D, Silverman LB, Sallan SE, Bradner JE, Hahn WC, Crispino JD, Pellman D, **Weinstock DM**. Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 lysine 27 trimethylation. *Nature Genetics* 2014;46:618-23.
53. Shanmugam I, Abbas M, Ayoub F, Mirabal S, Bsaili M, Caulder EK, **Weinstock DM**, Tomkinson AE, Hromas R, Shaheen M. Ubiquitin specific peptidase 20 regulates Rad17 stability, checkpoint kinase 1 phosphorylation and DNA repair by homologous recombination. *J Biol Chem* 2014; 289(33):22739-48.
54. Huang T-C, Civin C, Gojo I, Cutler J, Bharne S, Zhong J, **Weinstock D**, Tyner JW, Pandey A. Integrated Analysis of CRLF2 Signaling in Acute Lymphoblastic Leukemia Identifies Polo-Like Kinase 1 as a Potential Therapeutic Target. *Leuk Lymphoma* 2014;5:1-4.

55. Yoda A, Adelmant G, Tamburini J, Chapuy B, Shindoh N, Yoda Y, Weigert O, Kopp N, Wu S-C, Kim SS, Liu H, Tivey T, Christie AL, Elpek KG, Card J, Kritsman K, Gotlib J, Deininger MW, Makishima H, Turley SJ, Javidi-Sharifi N, Maciejewski JP, Jaiswal S, Ebert BL, Rodig SJ, Tyner JW, Marto JA, **Weinstock DM**<sup>^</sup>, Lane A<sup>^\*</sup>. Mutations in G protein beta subunits promote transformation and kinase inhibitor resistance. *Nature Med* 2015;21:71-5. <sup>^</sup>equal contribution. <sup>\*</sup>trainee in the Weinstock laboratory.
56. Schatz JH, Horwitz SM, Teruya-Feldstein J, Lunning M, Viale A, Huberman K, Socci ND, Lailier N, Heguy A, Dolgalev I, Migliacci JC, Pirum N, Palomba ML, **Weinstock DM**, Wendel HG. Targeted Mutational Profiling of Peripheral T-Cell Lymphoma Not Otherwise Specified Highlights New Mechanisms in a Heterogeneous Pathogenesis. *Leukemia* 2015;29:237-41.
57. Mansour MR, Reed C, Eisenberg AR, Tseng JC, Twizere JC, Daakour S, Yoda A, Rodig SJ, Tal N, Shochat C, Berezovskaya A, DeAngelo DJ, Sallan SE, **Weinstock DM**, Izraeli S, Kung AL, Kentsis A, Look AT. Targeting oncogenic interleukin-7 receptor signalling with N-acetylcysteine in T cell acute lymphoblastic leukaemia. *Br J Haematol* 2015;168:230-8.
58. Sujobert, P., Paubelle, E., Grenier, A., Zylbersztejn, F., Lambert, M., Poulain, L., Townsend, E., Brusq J-M., Nicodeme, E., Decropqc, D., Nepstad, I., Green A., Hospital, M-A., Jacque, N., Hermine, O., Foretz, M., Viollet, B., Lacombe, D., Mayeux, P., **Weinstock, D.M.**, Moura, I.C., Bouscary, D., Tamburini, J. Co-activation of AMPK and mTORC1 is synthetically lethal in acute myeloid leukemia. *Cell Reports* 2015;11:1446-57.
59. Green AS, Maciel TT, Hospital MA, Yin C, Mazed F, Townsend EC, Pilorge S, Lambert M, Paubelle E, Jacquel A, Zylbersztejn F, Decroocq J, Poulain L, Sujobert P, Jacque N, Adam K, So JC, Kosmider O, Auberger P, Hermine O, **Weinstock DM**, Lacombe C, Mayeux P, Vanasse GJ, Leung AY, Moura IC, Bouscary D, Tamburini J. Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia. *Sci Adv* 2015;1:e1500221.
60. Pastore A, Jurinovic V, Kride R, Hoster E, Staiger AM, Szczepanowski M, Pott C, Kopp N, Murakami M, Horn H, Leich E, Moccia AA, Mottok A, Sunkavalli A, van Hummelen P, Ducar M, Ennishi D, Shulha HP, Hother C, Connors JM, Sehn LH, Dreyling M, Neuberg D, Moller P, Feller AC, Hansmann ML, Stein H, Rosenwald A, Ott G, Klapper W, Unterhalt M, Hiddemann W, Gascoyne RD<sup>^</sup>, **Weinstock DM**<sup>^</sup>, Weigert O<sup>^</sup>. Integration of Gene Mutations Improves Risk Prognostication in Patients Receiving First-line Immunochemotherapy for Follicular Lymphoma in Clinical Trial and Population-Based Cohorts. *Lancet Oncol* 2016;16:1111-22. <sup>^</sup>equal contribution
61. Wu S-C, Li LS, Kopp N, Montero J, Chapuy B, Yoda A, Christie AL, Liu H, Christodoulou A, van Bodegom D, van der Zwet J, Layer JV, Tivey T, Lane AA, Ryan JA, Ng SY, DeAngelo DJ, Stone RM, Steensma D, Wadleigh M, Harris M, Mandon E, Ebel N, Andraos R, Romanet V, Dolemeyer A, Sterker D, Zender M, Rodig SJ, Murakami M, Hofmann F, Kuo F, Eck MJ, Silverman LB, Sallan SE, Letai A, Baffert F, Vangrevelinghe E, Radimerski T, Gaul C, **Weinstock DM**. Activity of the Type II JAK2 inhibitor CHZ868 in B-cell acute lymphoblastic leukemia. *Cancer Cell* 2015;28:29-41. Cover image for the 7/13/15 issue of *Cancer Cell*: [https://www.cell.com/cancer-cell/issue?pii=S1535-6108\(14\)X0019-X](https://www.cell.com/cancer-cell/issue?pii=S1535-6108(14)X0019-X).

62. Akahane K, Sanda T, Mansour M, Radimerski T, DeAngelo D, **Weinstock DM**, Look AT. HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia. *Leukemia* 2016;30(1):219-28.
63. Choi YE, Meghani K, Brault ME, Leclerc L, He YJ, Day TA, Elias KM, Drapkin R, **Weinstock DM**, Dao F, Shih KK, Matulonis U, Levine DA, Konstantinopoulos PA, Chowdhury D. Platinum and PARP inhibitor resistance due to overexpression of MicroRNA-622 in BRCA1-mutant ovarian cancer. *Cell Rep* 2016;14:429-39.
64. Chapuy B, Cheng H, Watahiki A, Ducar MD, Tan Y, Chen L, Roemer MG, Ouyang J, Christie AL, Zhang L, Gusenleitner D, Abo RP, Farinha P, von Bonin F, Thorner AR, Sun HH, Gascoyne RD, Pinkus GS, van Hummelen P, Wulf GG, Aster JC, **Weinstock DM**, Monti S, Rodig SJ, Wang Y, Shipp MA. Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biologic heterogeneity of the disease. *Blood* 2016;127:2203-13.
65. Monterzhadat V, **Weinstock DM**<sup>^</sup>, Lo A<sup>^</sup>. Buying cures versus renting health: Financing healthcare via consumer healthcare loans. *Sci Transl Med* 2016 Feb 24;8(327):327ps6. <sup>^</sup>equal contribution
66. Bernasconi-Elias P, Hu T, Jenkins D, Firestone B, Gans S, Kurth E, Capodieci P, Deplazes-Lauber J, Petropoulos K, Thiel P, Ponsel D, Hee Choi S, LeMotte P, London A, Goetschkes M, Nolin E, Jones MD, Slocum K, Kluk MJ, **Weinstock DM**, Christodoulou A, Weinberg O, Jaehrling J, Ettenberg SA, Buckler A, Blacklow SC, Aster JC, Fryer CJ. Characterization of activating mutations of NOTCH3 in T cell acute lymphoblastic leukemia and anti-leukemic activity of NOTCH3 inhibitory antibodies. *Oncogene* 2016;35:6077-86.
67. Townsend EC, Murakami MA, Christodoulou A, Christie AL, Koester J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu S-C, Plana O, Montero J, Stevenson KE, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf N, LaCasce AS, Lees E, Li L, Look AT, Murakami M, Mischen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnoli M, Ritz J, Brown M, Long H, Aster JC, Shipp M, Griffin JD, **Weinstock DM**. The Public Repository of Xenografts (PRoXe) enables discovery and randomized phase II-like trials in mice. *Cancer Cell* 2016;29:574-86.  
Corrigendum: *Cancer Cell* 2016;30:183.
68. Wu H, Wang A, Qi Z, Li X, Chen C, Yu K, Zou F, Hu C, Wang W, Zhao Z, Wu J, Liu J, Liu X, Wang L, Wang W, Zhang S, Stone RM, Galinsky IA, Griffin JD, **Weinstock D**, Christodoulou A, Wang H, Shen Y, Zhai Z, Weisberg EL, Liu J, Liu Q. Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML. *Leukemia* 2016;30:2112-6.
69. Louissaint A, Schafernack K, Geyer J, Kovach AEE, Ghandi M, Gratzinger D, Roth CG, Paxton CN, Kim S, Namgyal C, Morgan EA, Neuberg DS, South S, Harris MH, Hasserrjian RP, Hochberg EP,

Garraway LA, Harris NL, **Weinstock DM**. Pediatric-Type Nodal Follicular Lymphoma is a Biologically Distinct Variant of Lymphoma in Children and Adults With Frequent MAP Kinase Pathway Mutations. *Blood* 2016;128:1112-20.

70. Melchardt T, Hufnagl C, **Weinstock DM**, Kopp N, Neureiter D, Tränkenschuh W, Hackl H, Weiss L, Rinnerthaler G, Hartmann TN, Greil R, Weigert O, Egle E. Clonal evolution in relapsed and refractory diffuse large B cell lymphoma is characterized by high dynamics of subclones. *Oncotarget* 2016;9:51494-51502.

71. Cermak N, Olcum S, Delgado FF, Wasserman SC, Payer KR, Ogawa M, Kimmerling RJ, Stevens MM, Murakami MA, Kikuchi Y, Sandikci, **Weinstock DM**, Manalis SR. High-throughput growth measurements on single cells via serial microfluidic mass sensor arrays. *Nat Biotech* 2016;34:1052-9.

72. Jurinovic V, Kridel R, Staiger AM, Szczepanowski M, Horn H, Dreyling MH, Rosenwald A, Ott G, Klapper W, Zelenetz AD, Barr PM, Friedberg JW, Ansell S, Sehn LH, Connors JM, Gascoyne RD, Hiddemann W, Unterhalt M, **Weinstock DM**, Weigert O. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. *Blood* 2016;128:1112-20.

73. Morgan EA, Sweeney MP, Tomoka T, Kopp N, Gusenleitner D, Redd RA, Carey CD, Masamba L, Kamiza S, Pinkus GS, Neuberg DS, Rodig SJ, Milner DA, **Weinstock DM**. Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities. *Blood Advances* 2016;1(1):84-92.

74. Jacobson CA, Kopp N, Laver JV, Redd RA, Tschuri S, Haebe S, van Bodegom D, Bird L, Christie AL, Christodoulou A, Conway A, Tivey T, Zapf T, Dararia D, Zimmer-Strobl U, Rodig SJ, Weigert O, **Weinstock DM**. HSP inhibition overcomes ibrutinib resistance in mantle cell lymphoma. *Blood*. 2016 Nov 24;128(21):2517-2526.

75. Stevens MM<sup>^</sup>, Maire CL<sup>^</sup>, Chou N<sup>^</sup>, Murakami MA<sup>^</sup>, Knoff DS, Kikuchi Y, Kimmerling, RJ, Liu H, Haidar S, Calistri NL, Cermak N, Olcum S, Cordero NA, Idbah A, Wen PY, **Weinstock DM**<sup>^</sup>, Ligon KL<sup>^</sup>, Manalis SR<sup>^</sup>. Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate. *Nat Biotech* 2016;34:1161-7. <sup>^</sup>equal contribution

76. Dunford A<sup>^</sup>, **Weinstock DM**<sup>^</sup>, Savova V, Schumacher SE, Cleary JP, Yoda A, Sullivan TJ, Gimelbrant AA, Beroukhim R, Lawrence MS<sup>^</sup>, Getz G<sup>^</sup>, Lane AA<sup>^\*</sup>. Tumor-suppressor genes that escape X-inactivation contribute to cancer sex bias. *Nat Genet* 2017;49:10-16. <sup>^</sup>equal contribution. <sup>\*</sup>trainee in the Weinstock laboratory.

77. Herrera AF, Mei M, Low L, Kim HT, Griffin GK, Song JY, Merryman RW, Bedell V, Pak C, Sun H, Paris T, Stiller T, Brown JR, Budde LE, Chan WC, Chen R, Davids MS, Freedman AS, Fisher DC, Jacobsen ED, Jacobson CA, LaCasce A, Murata-Collins J, Nademanee AP, Palmer JM, Pihan GA, Pillai R, Popplewell L, Siddizi T, Sohani AR, Zain J, Rosen ST, Kwak LW, **Weinstock DM**, Forman SJ, Weisenburger DD, Kim Y, Rodig SJ, Krishnan A, Armand P. Relapsed or refractory double-expressor and double-hit lymphomas have inferior progression-free survival after autologous stem cell transplantation. *J Clin Onc* 2017;35:24-31.

78. Pikman Y, Alexe G, Roti G, Conway AS, Furman A, Lee AS, Place AE, Kim S, Saran C, Modiste R, **Weinstock DM**, Harris M, Kung AL, Silverman LB, Stegmaier K. Synergistic drug combinations with a CDK4/6 inhibitor in T-cell acute lymphoblastic leukemia. *Clin Cancer Res* 2017;23:1012-24.

79. Akahane K, Li Z, Etchin J, Berezovskaya A, Gjini E, Masse CE, Miao W, Rocnik J, Kapeller R, Greenwood JR, Tiv H, Sanda T, **Weinstock DM**, Look AT. Anti-leukemic activity of the TYK2 selective inhibitor NDI-031301 in T-cell acute lymphoblastic leukemia. *Brit J Haematol* 2017;177:271-82.
80. Ajore R, Raiser D, McConkey M, Joud M, Boidol B, Mar B, Saksena G, **Weinstock DM**, Armstrong S, Ellis SR, Ebert BL, Nilsson B. Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially *in concert* with *TP53* mutations. *EMBO Mol Med* 2017;9:498-507.
81. Day TA, Layer JV, Cleary JP, Guha S, Stevenson KE, Tivey T, Kim S, Schinzel AC, Izzo F, Doench J, Root DE, Hahn WC, Price BD, **Weinstock DM**. PARP3 is a promoter of chromosomal rearrangements and limits G4 DNA. *Nature Commun* 2017;8:15110.  
Corrigendum 2017;8:15918.
82. Rolland DCM, Basrur V, Jeon YK, McNeil-Schwalm C, Fermin D, Conlon KP, Zhou Y, Ng SY, Tsou CC, Brown NA, Thomas DG, Bailey NG, Omenn GS, Nesvizhskii AI, Root DE, **Weinstock DM**, Faryabi RB, Lim MS, Elenitoba-Johnson KSJ. Functional proteogenomics reveals biomarkers and therapeutic targets in lymphomas. *Proc Natl Acad Sci* 2017;114:6581-6.
83. Weisberg EL, Puissant A, Stone R, Sattler M, Buhrlage SJ, Yang J, Manley PW, Meng C, Buonopane M, Daley JF, Lazo S, Wright R, **Weinstock DM**, Christie AL, Stegmaier K, Griffin JD. Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. *Oncotarget* 2017;8:52026-44.
84. Weisberg EL, Schauer N, Yang J, Lamberto I, Doherty L, Bhatt S, Nonami A, Meng C, Letai A, Wright R, Tiv H, Goghale PC, Ritorto MS, De Cesar V, Trost M, Christodoulou A, Christie A, **Weinstock DM**, Adamia S, Stone RM, Chauhan D, Anderson KC, Seo H-S, Dhe-Paganon S, Sattler M, Gray N, Griffin JD, Buhrlage SJ. Inhibition of USP10 induces degradation of oncogenic FLT3. *Nat Chem Biol* 2017;13:1207-15.
85. Sewastianik T, Jiang M, Sukhdeo K, Patel SJ, Roberts K, Kang Y, Alduaij A, Dennis PS, Lawney B, Liu R, Song Z, Xiong J, Zhang Y, Lemieux ME, Pinkus G, Rich JN, **Weinstock DM**, Mullighan CG, Sharpless NE, Carrasco RD. Constitutive Ras signaling and *Ink4a/Arf* inactivation cooperate during the development of B-ALL in mice. *Blood Advances* 2017;1:2361-74.
86. Ryan RJ, Petrovic J, Rausch D, Zhou Y, Lareau C, Kluk MJ, Christie AL, Lee W, Tarjam D, Guo B, Donohue LK, Gillespie S, Nardi V, Hochberg EP, Blacklow SC, **Weinstock DM**, Faryabi RB, Bernstein BE, Aster JC, Pear WS. A B-cell regulome links Notch to downstream oncogenic pathways in small B cell lymphomas. *Cell Reports* 2017;21:784-97.
87. Meehan TF, Conte N, Goldstein T, Inghirami G, Murakami MA, Brabetz S, Gu Z, Wisner JA, Dunn P, Begley DA, Krupke DM, Bertotti A, Bruna A, Brush MH, Byrne AT, Caldas C, Christie AL, Clark DA, Dowst H, Dry JR, Doroshov JH, Duchamp O, Evrard YA, Ferretti S, Frese KK, Goodwin NC, Greenawald D, Haendel MA, Hermans E, Houghton PJ, Jonkers J, Kemper K, Khor TO, Lewis MT, Lloyd KCK, Mason J, Medico E, Neuhauser SB, Olson JM, Peeper DS, Rueda OM, Seong JK, Trusolino L, Vinolo E, Wechsler-Reya RJ, **Weinstock DM**, Welm A, Weroha SJ, Amant F, Pfister



SM, Kool M, Parkinson H, Butte AJ, Bult CJ. PDX-MI: minimal information for patient-derived tumor xenograft models. *Cancer Res.* 2017;77:e62-e66.

88. Herrera AF, Rodig, SJ, Song JY, Kim Y, Griffin GK, Yang D, Nikolaenko L, Mei M, Bedell V, Dal Cin P, Pak C, Aleya EP, Budde LE, Chen R, Chen Y-B, Chan WC, Cutler CS, Ho VT, Koreth J, Krishnan A, Murata-Collins JL, Nikiforow S, Palmer J, Pihan GA, Pillai R, Popplewell L, Rosen ST, Siddiqi T, Sohani AR, Zain J, Kwak LW, Weisenburger DD, **Weinstock DM**, Soiffer RJ, Antin JH, Nademanee AP, Armand P. Outcomes after allogeneic stem cell transplantation in patients with double-hit and double-expressor lymphoma. *Biol Blood Marrow Transplant* 2018;24: 514-520.

89. Horwitz SM, Koch R, Porcu P, Oki Y, Moskowitz A, Perez M, Myskowski P, Officer A, Jaffe JD, Morrow SN, Allen K, Douglas M, Stern H, Sweeney J, Kelly P, Kelly V, Aster JC, Weaver D, Foss FM<sup>^</sup>, **Weinstock DM**<sup>^</sup>. Activity of the PI3K- $\delta,\gamma$  inhibitor Duvelisib in a phase I trial and preclinical models of T-cell lymphoma. *Blood* 2018;131:855-863. <sup>^</sup>equal contribution

90. Zhang Q, Shi C, Han L, Jain N, Roberts KG, Ma H, Tai C, Cavazos A, Park E, Tabe Y, Jacamo RO, Mu H, Zhao Y, Wang J, Wu S-C, Cao F, Zeng Z, Zhou J, Mi Y, Jabbour EJ, Radimerski T, Levine R, Müschen M, Tasian SK, Mullighan CG, **Weinstock DM**, Fruman DA, Konopleva M. Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in *CRLF2* rearranged and/or *JAK* driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia. *Oncotarget* 2018;9:8027-41.

91. Cooper M, Choi J, Staser K, Ritchey J, Niswonger J, Eckardt K, Rettig M, Wang B, Eissenberg L, Ghobadi A, Gehrs L, Prior J, Achilefu S, Miller C, Fronick C, O'Neal J, Gao F, **Weinstock DM**, Gutierrez A, Fulton R, Dipersio J. An 'off-the-shelf' fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. *Leukemia* 2018;32:1970-83.

92. Xiao G, Chan LN, Klemm L, Braas D, Chen Z, Geng H, Zhang QC, Aghajani-refah A, Cosgun KN, Sadras T, Lee J, Mirzapooiazova T, Salgia R, Ernst T, Hochhaus A, Jumaa H, Jiang X, **Weinstock DM**, Graeber TG, Müschen M. B-cell-specific diversion of glucose carbon utilization reveals a unique therapeutic vulnerability of B cell malignancies. *Cell* 2018;173:470-4.

93. Zhou XA, Wenzel A, Louissaint A, Yang J, Martinez-Escala ME, Guitart J, Behdad A, Cerroni L, **Weinstock DM**, Choi J. Genomic analyses identify recurrent alterations in immune evasion genes in diffuse large B-cell lymphoma, leg type. *J Invest Dermatol* 2018;138:2365-76.

94. Chiaretti S, Messina M, Grammatico S, Piciocchi A, Fedullo AL, Di Giacomo F, Peragine N, Gianfelici V, Lauretti A, Bareja R, Martelli MP, Vignetti M, Apicella V, Vitale A, Salek C, Elemento O, Inghirami G, **Weinstock DM**, Guarini A, Foa R. Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications. *Brit J Haematol* 2018;181:642-52.

95. Ng SY, Yoshida N, Christie AL, Ghandi M, Dharia NV, Dempster J, Murakami M, Shigemori K, Morrow SN, Van Scoyk A, Cordero NA, Stevenson KE, Puligandla M, Haas B, Lo C, Meyers R, Gao G, Cherniack A, Louissaint A, Nardi V, Thorner AR, Long H, Qiu X, Morgan EA, Dorfman DM, Fiore D, Jang J, Epstein AL, Dogan A, Zhang Y, Horwitz SM, Jacobsen ED, Santiago S, Ren J-G, Guerlavais V, Annis DA, Aivado M, Saleh MN, Mehta A, Tsherniak A, Root D, Vazquez F, Hahn WC, Inghirami G, Aster JC, **Weinstock DM**<sup>^</sup>, Koch R<sup>^\*</sup>. Targetable vulnerabilities in T- and NK-cell lymphomas

identified through preclinical models. Nat Commun 2018;22:2024. ^equal contribution. \*trainee in the Weinstock laboratory.

96. Ng SY, Brown L, Stevenson KE, Aster JC, DeSouza T, Louissaint, **Weinstock DM**. RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in mice. Blood 2018;132:935-47.

Cover image for the August 30, 2018 edition: <http://www.bloodjournal.org/content/132/9.cover-expansion>.

97. Craig JW, Mina MJ, Crombie JL, LaCasce AS, **Weinstock DM**, Pinkus GS, Pozdnyakova O. Assessment of CD52 expression in “double-hit” and “double-expressor” lymphomas: implications for clinical trial eligibility. PLoS One 2018 Jul 18;13(7):e0199708.

98. Scarfò I, Ormhøj M, Frigault MJ, Castano AP, Lorrey S, Bouffard AA, van Scoyk A, Rodig SJ, Shay AJ, Aster JC, Preffer FI, **Weinstock DM**, Maus MV. Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. Blood 2018;132:1495-1506.

99. Hellmuth JC, Louissaint A, Szczepanowski M, Haebe S, Pastore A, Aligi S, Staiger AM, Hartmann S, Kridel R, Ducar MD, Koch P, Dreyling M, Hansmann M-L, Ott G, Rosenwald A, Gascoyne RD, **Weinstock DM**, Hiddemann W, Klapper W, Weigert O. Duodenal-type and nodal follicular lymphoma differ by their immune microenvironment rather than their mutation profiles. Blood 2018;132(16):1695-1702.

100. Layer JV, Cleary JP, Brown AJ, Stevenson KE, Van Scoyk A, Morrow SN, Blasco RB, Karaca E, Meng F-L, Frock RL, Tivey T, Kim S, Fuchs H, Chiarle R, Alt FW, Roberts SA, **Weinstock DM**<sup>^</sup>, Day TA.<sup>^\*</sup> Parp3 promotes long-range end-joining in murine cells. Proc Natl Acad Sci USA 2018 115:10076-81. ^co-corresponding author. \*trainee in the Weinstock laboratory.

101. Koch R, Christie AL, Crombie JL, Palmer A, Plana D, Shigemori K, Morrow SN, Van Scoyk A, Wu W, Brem EA, Secrist JP, Drew L, Schuller A, Cidado J, Letai A, **Weinstock DM**. Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas. Blood 2019;133:566-75.

102. Dobrovolsky D, Wang ES, Morrow SN, Leahy C, Faust T, Nowak RP, Donovan KA, Yang G, Li Z, Fischer ES, Treon SP, **Weinstock DM**<sup>^</sup>, Gray NS<sup>^</sup>. Bruton tyrosine kinase degradation as a therapeutic strategy for cancer. Blood 2019;133:952-61. ^co-corresponding author.

103. Ghandi M, Huang FW, Jane-Valbuena J, Kyukov GV, Lo CC, McDonald ER III, Barretina J, Gelfand ET, Belski CM, Li H, Hu K, Andreev-Drakhlin AY, Kim J, Hess JM, Haas BJ, Aguet F, Weir BA, Rothberg MV, Paoletta BR, Lawrence MS, Akbani R, Lu Y, Tiv HL, Gokhale PC, deWeck A, Mansoru AA, Oh C, Shih J, Hadi K, Rosen Y, Bistline J, Venkatesan K, Reddy A, Sonkin D, Liu M, Lehar J, Korn J, Porter DA, Jones MD, Gorji J, Caponigro G, Taylor JE, Dunning CM, Creech AL, Warren A, McFarland J, Zamanighomi M, Kauffmann A, Stransky N, Imielinski M, Maruvka YE, Cherniack AD, Tscherniak A, Vazquez F, Jaffe JD, Lane AA, **Weinstock DM**, Johnanessen CM, Morrissey MP, Stegmeier F, Schlegel R, Hahn WC, Getz G, Mills GB, Boehm JS, Golub TR, Garraway LA, Sellers WR. Next generation characterization of the cancer cell line encyclopedia. Nature 2019;569:503-8.

104. Lossos C, Liu Y, Kolb KE, Christie AL, van Scoyk A, Prakadan SM, Shigemori K, Stevenson KE, Morrow S, Plana OD, Fraser C, Jones KL, Liu H, Pallasch CC, Modiste R, Nguyen Q-D, Craig

JW, Morgan EA, Vega F, Aster JC, Sarosiek K, Shalek AK, Hemann MT, **Weinstock DM**. Mechanisms of lymphoma clearance induced by high-dose alkylating agents. *Cancer Discovery* 2019;9:944-61.

105. Pouliot GP, Degar J, Hinze L, Kochupurakkal B, Vo CD, Burns MA, Moreau L, Ganesa C, Roderick J, Peirs S, Menten B, Loh ML, Hunger SP, Silverman LB, Harris MH, Stevenson KE, **Weinstock DM**, Weng AP, Kelliher MA, van Vlierberghe P, D'Andrea AD, Gutierrez A. Fanconi-BRCA pathway mutations in childhood T-cell acute lymphoblastic leukemia. *PLoS One* 2019;14:e0221288.

106. Jain S, Van Scoyk A, Morgan EA, Matthews A, Stevenson K, Netwon G, Powers F, Autio A, Louissaint A, Pontini G, Aster JC, Luscinskas FW, **Weinstock DM**. Targeted inhibition of CD47-SIRP $\alpha$  requires Fc-Fc $\gamma$ R interactions to maximize activity in T-cell lymphomas. *Blood* 2019;134:1430-40.

107. Togami K, Pastika T, Stephansky J, Ghandi M, Christie AL, Jones KL, Johnson CA, Lindsay RW, Brooks CL, Letai A, Craig JW, Pozdnyakova O, **Weinstock DM**, Montero J, Aster JC, Johannessen CM, Lane AA. DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance. *J Clin Inv* 2019;129:5005-19.

108. Ormhøj M, Scarfò I, Cabral ML, Bailey SR, Lorrey SJ, Bouffard AA, Castano AP, Larson RC, Riley LS, Schmidts A, Choi BD, Andersen RS, Cédile O, Nyvold CG, Haaber J, Gjerstorff MF, Ditzel HJ, **Weinstock DM**, Barington T, Frigault MJ, Maus MV. Chimeric antigen receptor T cells targeting CD79b show efficacy in lymphoma with or without cotargeting CD19. *Clin Cancer Res* 2019;25:7046-57.

109. Beheshti A, Stevenson K, Vanderburg C, Ravi D, McDonald JT, Christie AL, Shigemori K, Jester H, **Weinstock DM**, Evens AM. Identification of circulating serum multi-microRNA signatures in human DLBCL models. *Scientific Rep* 2019;9:17161.

110. Cidado J, Boiko S, Proia T, Ferguson D, Criscione SW, San Martin M, Pop-Damkov P, Su N, Roamia Franklin VN, Reddy Chilamakuri CS, D'Santos CS, Shao W, Saeh J, Koch R, **Weinstock DM**, Zinda M, Fawell S, Drew L. AZD4573 is a highly selective CDK9 inhibitor that suppresses MCL-1 and induces apoptosis in hematological cancer cells. *Clin Cancer Res* 2020;26:922-34.

111. Yoshida N, Shigemori K, Donaldson N, Cordero NA, Stevenson KE, Bu X, Arakawa F, Takeuchi M, Ohshima K, Yoda A, Ng SY, **Weinstock DM**. Genomic landscape of young ATLL patients identifies frequent targetable CD28 fusions. *Blood* 2020;135:1467-71.

112. Pikman Y, Conway A, Robichaud A, Kitara S, Church A, Kennedy A, Silverman L, Billett A, **Weinstock DM**, Harris M, Stegmaier K. Targeting EZH2 for the treatment of hepatosplenic T-cell lymphoma. *Blood Advances* 2020;4:1265-9

113. Chan LN, Murakami M, Caeser R, Hurtz C, Kume K, Sadras T, Shojaee S, Hong C, Pölönen P, Nix MA, Ugale A, Chen Z, Lee J, Cosgun KN, Geng H, Chen CW, Chen J, Vogt A, Heinaniemi M, Lohi O, Wiita AP, Izraeli S, Graeber TG, **Weinstock DM**, Müschen M. Signaling input from divergent pathways prevents malignant B-cell transformation. *Nature* 2020;583:845-51.

114. Barraria D, Hildebrand JA, Stolz S, Haebe S, Alig S, Trevisani CP, Osorio-Barros F, Bartoschek MD, Bosl M, Pastore A, Gaitzsch E, Heide M, Jurinovic V, Rautter K, Guanwardana J, Sabdia M, Szczepanowski M, Richter J, Klapper W, Louissaint A, Ludwig C, Bultmann S, Leonhardt H, Eustermann S, Hopfner K-P, Hiddemann W, von Bergwelt M, Steidl C, Kridel R, Tobin JWD, Gandhi MK, **Weinstock DM**, Schmidt-Supprian M, Sarosi MB, Rudelius M, Passerini V, Mautner J, Weigert O. Cathepsin S alterations induce a tumor-promoting immune microenvironment in follicular lymphoma. *Cell Reports* 2020;31:107522.
115. Fiore D, Cappelli V, Zumbo P, Phillip JM, Liu A, Cheng S, Yoffe L, Ghione P, Di Maggio F, Dogan A, Khodo I, de Stanchina E, Casano C, Kayembe C, Tam M, Betel D, Foa R, Cerchietti L, Rabadan R, Horwitz SM, **Weinstock DM**, Inghirami GG. A novel JAK1 mutant breast implant-associated anaplastic large cell lymphoma patient-derived xenograft fostering pre-clinical discoveries. *Cancers* 2020;12:E1603.
116. He Y, Koch R, Budamagunta V, Zhang P, Zhang X, Khan S, Thummuri D, Ortiz YT, Zhang X, Dongwen L, Wiegand JS, Li W, Palmer AC, Zhen G, **Weinstock DM**<sup>^</sup>, Zhou D<sup>^</sup>. DT2216 – a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. *J Hemat Onc* 2020;13:95. <sup>^</sup>co-corresponding author
117. Lee, J, Robinson ME, Ma N, Artadji D, Ahmed MA, Xiao G, Sadras T, Deb G, Winchester J, Cosgun KN, Geng H, Chan LN, Kume K, Miettinen TP, Zhang Y, Nix MA, Klemm L, Chen CW, Chen J, Khairnar V, Wiita AP, Thomas-Tikhonenko A, Farzan M, Jung JU, **Weinstock DM**, Manalis SR, Diamond MS, Vaidehi N, Müschen M. IFITM3 functions as a PIP3-scaffold to amplify PI3K signaling in B cells. *Nature* 2020;588:491-7.
118. Layer JV, Debaize L, Van Scoyk A, House N, Brown AJ, Liu Y, Stevenson KE, Hemann M, Roberts SA, Price B, **Weinstock DM**<sup>^</sup>, Day TA<sup>^</sup>. Polymerase  $\delta$  promotes chromosomal rearrangements and imprecise double-strand break repair. *Proc Natl Acad Sci USA* 2020;117:27566-77. <sup>^</sup>co-corresponding author
119. Bhatt S, Pioso MS, Olesinski EA, Yilma B, Ryan JA, Mashak T, Leutz B, Adamia S, Zhu H, Kuang Y, Mogili A, Louissaint AJ, Bohl SR, Mehta AK, Sanghavi S, Wang Y, Morris E, Halilovic E, Paweletz CP, **Weinstock DM**, Garcia JS, Letai A. Reduced mitochondrial apoptotic priming drives resistance to BH3 mimetics in acute myeloid leukemia. *Cancer Cell* 2020;38:872-90.
120. Koschut D, Ray D, Li Z, Giarin E, Grot J, Alic I, Kham SK-Y, Chng WJ, Ariffin H, **Weinstock DM**, Yeoh AE-J, Basso G, Nizetic D. RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemia. *Oncogene* 2021;40:746-62.
121. Zhao XA, Yang J, Ringbloom KG, Martinez-Escala ME, Stevenson KE, Wenzel AT, Fantini D, Martin H, Moy AP, Morgan EA, Harkins S, Paxton CN, Hong B, Andersen EF, Guitart J, **Weinstock DM**, Cerroni L, Choi J, Louissaint A. Genomic landscape of cutaneous follicular lymphomas reveals 2 subgroups with clinically predictive molecular features. *Blood Adv* 2021;5:649-61.
122. Valvert F, Silva O, Solórzano E, Puligandla M, Siliézar Tala MM, Guyon T, Dixon SL, López N, López F, Carias Alvarado CC, Terbrueggen R, Stevenson KE, Natkunam Y, **Weinstock DM**<sup>\*</sup>, Briercheck EL. Low-Cost, Transcriptional Diagnostic to Accurately Categorize Lymphomas in Low- and Middle-Income Countries. *Blood Adv* 2021;5:2447-55. <sup>\*</sup>Corresponding author.

123. Maliga Z, Nirmal AJ, Ericson NG, Boswell SA, U'Ren L, Podymingogin R, Chow J, Chen Y-A, Chen AA, **Weinstock DM\***, Lian CG, Murphy GF, Kaldjian EP, Santagata S, Sorger PK. Micro-region transcriptomics of fixed human tissue using Pick-Seq. bioRxiv posted March 19, 2021. <https://doi.org/10.1101/2021.03.18.431004>.
124. Zee BM, Poels KE, Yao C, Kawabata KC, Wu G, Duy C, Jacobus WB, Senior E, Endress JE, Jambhekar A, Lovitch SB, Ma J, Dhall A, Harris IS, Blanco MA, Sykes DB, Licht JD, **Weinstock DM**, Melnick A, Haigis MC, Michor F, Shi Y. Combined epigenetic and metabolic treatments overcome differentiation blockade in acute myeloid leukemia. *iScience* 2021;24:102561.
125. Lee K, Evans MG, Yang L, Ng S, Snowden C, Khodadoust M, Brown RA, Trum N, Querfeld C, Doan LT, Song J, Zhang H, Gru AA, Wood GS, Wada DA, Shanmugam V, Haun PL, Aster JC, Duncan LM, Guitart J, **Weinstock DM**, Nardi V, Choi J. Primary cytotoxic T cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway. *Blood* [*in press*].

#### Other peer-reviewed publications

1. **Weinstock DM**, Helgadottir HR, Nakankishi K, Jasin M. Assaying double-strand break repair pathway choice in mammalian cells using a targeted endonuclease or the RAG recombinase. *Methods Enzymology* 2006;409:524-39.
2. Fliedner TM, Chao NJ, Bader JL, Boettger A, Case C Jr, Chute J, Confer DL, Ganser A, Gorin NC, Gourmelon P, Graessle DH, Krawisz R, Meineke V, Niederwieser D, Port M, Powles R, Sirohi B, **Weinstock DM**, Wiley A, Coleman CN. Stem Cells, Multiorgan Failure in Radiation Emergency Medical Preparedness: A US/European Consultation Workshop. *Stem Cells* 2009;27:1205-11.
3. Davids MS, Case C Jr., Confer DL, Weisdorf DJ, **Weinstock DM**. Medical management of radiation victims in the United States. *Health Phys* 2010;98:833-7.
4. Coleman CN, Knebel AR, Hick JL, **Weinstock DM**, Cassagrande R, Caro JJ, DeRenzo EG, Dodgen D, Norwood AE, Sherman SE, Cliffer KD, McNally R, Bader JL, Murrain-Hill P. Scarce resources for nuclear detonation: project overview and challenges. *Disaster Med Public Health Prep* 2011;5:S13-9.
5. Knebel AR, Coleman CN, Cliffer KD, Murrain-Hill P, McNally R, Oancea V, Jacobs J, Buddemeier B, Hick JL, **Weinstock DM**, Hrdina CM, Taylor T, Matzo M, Bader JL, Livinski AA, Parker G, Yeskey K. Allocation of scarce resources after a nuclear detonation: setting the context. *Disaster Med Public Health Prep* 2011;5:S20-31.
6. DiCarlo AL, Maher C, Hick JL, Dainiak N, Chao N, Bader JL, Coleman CN, **Weinstock DM**. Radiation injury after a nuclear detonation: medical consequences and the need for scarce resources allocation. *Disaster Med Public Health Prep* 2011;5:S32-44.
7. Hick JL, **Weinstock DM**, Coleman CN, Hanfling D, Cantrill S, Redlener I, Bader JL, Murrain-Hill P, Knebel AR. Health care system planning for and response to a nuclear detonation. *Disaster Med Public Health Prep* 2011;5:S73-78.

8. Murrain-Hill P, Coleman CN, Hick JL, Redlener I, **Weinstock DM**, Koerner JF, Black D, Sanders M, Bader JL, Forsha J, Knebel AR. Medical response to a nuclear detonation: creating a playbook for state and local planners and responders. *Disaster Med Public Health Prep* 2011;5:S89-97.
9. **Weinstock DM**. Prophylactic hematopoietic cell harvesting in nuclear plant workers: the argument against. *Leuk Suppl* 2012;1:S42-43.
10. Coleman CN, Adams S, Adrianopoli C, Ansari A, Bader JL, Buddemeier B, Caro JJ, Casagrande R, Case C Jr, Caspary K, Chang AS, Chang HF, Chao N, Cliffer KD, Confer D, Deitchman S, Derenzo EG, Dobbs A, Dodgen D, Donnelly EH, Gorman S, Grace MB, Hatchett R, Hick JL, Hrdina C, Jones R, Kane E, Knebel A, Koerner JF, Laffan AM, Larson L, Livinski A, Mackinney J, Maidment BW, Manning R, Marinissen MJ, Martin C, Michael G, Murrain-Hill P, Nemhauser JB, Norwood AE, Nystrom S, Raheem M, Redlener I, Sheehan K, Simon SL, Taylor TP, Toner E, Wallace KS, Wieder J, **Weinstock DM**, Wiley AL Jr, Yeskey K, Miller CW, Whitcomb RC Jr. Medical Planning and response for a nuclear detonation: a practical guide. *Biosecur Bioterror* 2012;10:346-71.
11. Coleman CN, Sullivan JM, Bader JL, Murrain-Hill P, Koerner JF, Garrett AL, **Weinstock DM**, Case C Jr, Hrdina C, Adams SA, Whitcomb RC, Graeden E, Shankman R, Lant T, Maidment BW, Hatchett RC. Public health and medical preparedness for a nuclear detonation: the nuclear incident medical enterprise. *Healthy Phys* 2015;108:149-60.
12. Giwa S, Lewis JK, Alvarez L, Langer R, Roth AE, Church GM, Markmann JF, Sachs DH, Chandraker A, Wertheim JA, Rothblatt M, Boyden ES, Eidbo E, Lee WPA, Pomahac B, Brandacher G, **Weinstock DM**, Elliott G, Nelson D, Acker JP, Uygun K, Schmalz B, Weegman BP, Tocchio A, Fahy GM, Storey KB, Rubinsky B, Bischof J, Elliott JAW, Woodruff TK, Morris GJ, Demirci U, Brockbank KGM, Woods EJ, Ben RN, Baust JG, Gao D, Fuller B, Rabin Y, Kravitz DC, Taylor MJ, Toner M. The promise of organ and tissue preservation to transform medicine. *Nat Biotechnol* 2017;7:530-42.
13. Weigert O, **Weinstock DM**. The promises and challenges of using gene mutations for patient stratification in follicular lymphoma. *Blood* 2017;130:1491-8.  
Reprinted in special issue "Novel Treatment Approaches for Malignant Lymphoma: Selected Articles from the *Blood* Journal. 2018, pp.14-21.
14. Luskin M, Murakami MA, Manalis SR, **Weinstock DM**. Targeting minimal residual disease: a path to cure? *Nature Reviews Cancer* 2018;18:255-63.
15. Jacobsen E, **Weinstock DM**. Challenges and implications of genomics for T-cell lymphomas. *Hematology Am Soc Hematol Educ Program* 2018(1):63-8.
16. Coleman CN, Bader JL, Koerner JF, Hrdina C, Cliffer KD, Hick JL, James JJ, Mansoura MK, Livinski AA, Nystrom SV, DiCarlo-Cohen A, Marinissen MJ, Wathen L, Appller JM, Buddemeier B, Casagrande R, Estes D, Byrne P, Kennedy EM, Jakubowski AA, Case C, **Weinstock DM**, Dainiak N, Hanfling D, Garrett AL, Grant NN, Dodgen D, Redlener I, MacKay TF, Treber M, Homer MJ, Taylor TP, Miller A, Korch G, Hatchett R. Chemical, Biological, Radiological, Nuclear, and Explosive (CBRNE) Science and CBRNE Science Medical Operations Science Support Expert (CMOSSE). *Disaster Med Public Health Prep* 2019;13:995-1010.

Scholarship without named authorship

1. Gemtuzumab for relapsed acute myeloid leukemia. *Med Lett Drugs Ther* 2000;42:67-8. (uncited sole author)
2. Gleevec (STI-571) in chronic myeloid leukemia. *Med Lett Drugs Ther* 2001;43:49-50. (uncited sole author)
3. Lung cancer screening. *Med Lett Drugs Ther* 2001;43:61-2. (uncited sole author)
4. Pegfilgrastim for febrile neutropenia. *Med Lett Drugs Ther* 2002;44:44. (uncited sole author)
5. Azacytidine for myelodysplastic syndrome. *Med Lett Drugs Ther* 2005;46:11. (uncited sole author)
6. Erlotinib for advanced non-small cell lung cancer. *Med Lett Drugs Ther* 2005;46:25-6. (uncited sole author)
7. Lenalidomide for myelodysplastic syndrome with 5q cytogenetic abnormality. *Med Lett Drugs Ther* 2006;48:31-2. (uncited sole author)
8. Decitabine for myelodysplastic syndrome. *Med Lett Drugs Ther* 2006;48:91-2. (uncited sole author)
9. Dasatinib for Philadelphia chromosome-positive leukemias. *Med Lett Drugs Ther* 2007;49:5-6. (uncited sole author)
10. Nilotinib for CML. *Med Lett Drugs Ther* 2008;50:26-7. (uncited sole author)

[Non-peer reviewed scientific or medical publications/materials in print or other media](#)

Reviews, chapters, monographs and editorials

1. **Weinstock DM**, Sepkowitz KA. Multidrug-resistant tuberculosis and the health care worker. In: Bastian I, Portaels F (eds.) Multidrug-resistant tuberculosis. Dordrecht, The Netherlands: Kluwer Academic Publishers; 2000, pp. 225-40.2.
2. **Weinstock DM**, Straus DJ. Diagnostic problems in the evaluation of lymphadenopathy. *Prim Care Cancer* 2001;21(8).
3. **Weinstock DM**. State of the Art: Management of *Rhodococcus equi* infections [Perspectives, Contemporary Topics]. MD Consult Infectious Disease. September 26, 2002. Available at: <http://www.mdconsult.com>.
4. Crawford CV, **Weinstock DM**. State of the Art: Infections among Liver Transplant Recipients [Perspectives, Contemporary Topics]. MD Consult Infectious Disease. May 28, 2003. Available at: <http://www.mdconsult.com>.
5. **Weinstock DM**, Zuccotti G. Adamantane resistance in influenza A. *JAMA* 2006;295:934-6.

6. **Weinstock DM**, Zuccotti G. The evolution of influenza resistance and treatment. *JAMA* 2009;301:1066-9.
7. **Weinstock DM**. EBV, lymphoma-risk and the potential role of HIV-infection in IBD patients undergoing immunosuppression. *Digestive Diseases* 2010;28:519-24
8. Kamboj M, **Weinstock DM**. Epstein-Barr Virus, Varicella-Zoster Virus and Human Herpes Viruses-6 and -8. In: Safdar A (ed.). Principles and Practices of Infectious Diseases. New York, NY: Humana Press; 2011, pp. 359-370.
9. Confer DL, Weisdorf D, **Weinstock D**, Case C, Chao N. Radiation disasters: role of the BMT team. *Biol Blood Marrow Transp* 2012;18:S189-92.
10. Confer DL, Weisdorf D, **Weinstock D**, Case C, Chao N. Radiation disasters: role of the BMT team. *Biol Blood Marrow Transplant* 2012;18:S189-S192.
11. LaCasce A, **Weinstock DM**. Navigating Future Challenges in Lymphoma: A Map for the Road Ahead. *The Hematologist* May/June 2015;12(3):1,13.
12. Hatchett RJ, **Weinstock DM**, Goans RE. Radiation accidents and the medical management of acute radiation injury. In: Koenig and Schultz (ed.). Disaster Medicine: Comprehensive Principles and Practice. New York, NY: Cambridge University Press; 2016, pp. 545-579.
13. Yoshida N, **Weinstock DM**. It takes a village to unmask HSTL. *Cancer Disc* 2017;7:352-3.
14. Murakami M, **Weinstock DM**. Cancer models: the next best thing. *Nature* 2017;549:39-41.
15. Yoshida N, **Weinstock DM**. Clinicogenetic risk modeling in ATL. *Blood* 2018;131:159-160.
16. Horwitz SM, **Weinstock DM**. TFH lymphomas: the times they aza-changin? *Blood* 2019 134:1364-5.
17. Gewurz BE, Moulton E, Bessnow A, **Weinstock DM**, Bond S. EBV infection and posttransplant lymphoproliferative disease. In: Safdar, Amar (ed.). Principles and Practices of Transplant Infectious Diseases. New York, NY: Springer Press; 2019, pp.643-66.
18. Mundy-Bosse B, **Weinstock DM**. Breaking down the barriers to define and treat NK/T-cell lymphoma. *Cancer Cell* 2020;37:263-5.
19. **Weinstock D**. On grieving for the out-of-practice. *New Engl J Med* 2020;383:1809-11.

#### Letters to the Editor

1. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. **Weinstock DM**, Gubareva LV, Zuccotti G. *New Engl J Med* 2003;348:867-8.
2. Garces Ambrossi G, Jakubowski A, Feinstein M, **Weinstock DM**. Active tuberculosis limited to foreign-born patients after allogeneic hematopoietic stem cell transplant. *Bone Marrow Transplant* 2005;36:741-3.



3. **Weinstock DM**, Zuccotti G. Shift shown in influenza A resistance [reply]. *JAMA* 2006;296:1587.
4. **Weinstock DM**, Case C, Confer DL. Response: radiologic and nuclear events [reply]. *Blood* 2008;111:5758-9.
5. Weisdorf D, **Weinstock DM**, Case C, Chao N, Confer DL. Planning and response to radiation disasters. *Biol Blood Marrow Trans* 2011;17:126203.
6. **Weinstock DM**. Prophylactic hematopoietic cell harvesting in nuclear plant workers: the argument against. *Leukemia Supp* 2012;1:S42-3.
7. **Weinstock DM**, Dalla Favera R, Gascoyne RD, Leonard JP, Levy R, Lossos IS, Melnick AM, Nowakowski GS, Press OW, Savage KJ, Shipp MA, Staudt LM. A roadmap for discovery and translation in lymphoma. *Blood* 2015;125: 2175-7.

### Clinical Guidelines and Reports

1. Clinical guidelines for antibiotic prophylaxis and use in autologous and allogeneic stem cell transplant recipients, Allogeneic Bone Marrow Transplant and Infectious Diseases Services, Memorial Sloan-Kettering Cancer Center, 2007.

### Narrative Report

I am Lavine Family Chair of Preventative Medicine at DFCI, an Associate Physician in Medical Oncology at BWH, and a Professor of Medicine and Pediatrics at HMS. My major activities are devoted to basic and translational research, teaching, mentoring, clinical care and administration. My research concentrates on the pathobiology of lymphoid malignancies and their rational targeting with therapeutics. These studies have resulted in several pioneering publications and many ongoing projects. I co-lead the Dana-Farber/Harvard Cancer Center Leukemia Program. My teaching and mentoring include lectures to graduate and medical students, serving as an instructor in graduate school courses, and mentoring students and postdoctoral fellows within my laboratory. My clinical responsibilities include the care of patients undergoing blood and marrow transplantation. I am an elected, at-large Member of the HMS/HDMS Faculty Council, which advises the Dean on matters related to the faculty and co-chair the Subcommittee on Climate Change and Sustainability.

### Area of Excellence: Investigation

(a) Identifying and targeting vulnerabilities in lymphoid neoplasms. My laboratory, which currently includes approximately 20 students, fellows, and professional scientists, established a functional screen to identify mutated genes directly from tumors that can promote proliferation and survival in cells. Among our discoveries with that approach was that the cytokine receptor CRLF2 is altered in about 5-10% of acute lymphoblastic leukemia (ALL) cases. We went on to show that CRLF2 alterations confer a poor prognosis, that they result from a specific mechanism of DNA breakage and repair, and that they activate multiple pathway of signaling in the cancer cell. We subsequently identified mutations of G protein beta subunits across a range of different cancers that drive transformation and resistance to kinase inhibitors. Recently, we defined the biology of a rare subtype of follicular lymphoma, established a clinicogenetic prognostic model for follicular lymphoma, co-developed a strategy to define therapeutic sensitivity of single leukemia cells, and demonstrated the potential for next-generation lymphoma

diagnostics in lower- and middle-income countries. Work from our lab has led to several clinical trials that are currently open or under Institutional Review Board review. I lead an NCI Program Project Grant that includes DFCI, Duke University, Yale University and City of Hope Medical Center. We work with additional affiliated centers (Nebraska, Stanford, University of Miami, Fred Hutchinson Cancer Research Center, Washington University, Ohio State) to develop new strategies for targeting T-cell lymphomas. I co-lead the Dana-Farber/Harvard Cancer Center Leukemia Program that extends across DFCI, BWH, BCH, MGH, HMS, Beth Israel/Deaconess Medical Center and affiliated centers.

(b) Applying patient-derived models of hematologic neoplasms to define biology and therapeutic vulnerabilities. We utilize a system that allows for the growth of human leukemias in mice, which affords the opportunity to test targeted therapeutics against these leukemias within a living animal. We have established a panel of >350 human leukemias and lymphomas that grow in mice. We have utilized these models to orchestrate phase II-like pre-clinical trials completely in mice. Ongoing studies are defining biomarkers of response and mechanisms of resistance to a range of therapies. We have made the models available through an open-source web portal ([www.PRoXe.org](http://www.PRoXe.org)), which has been accessed by researchers from >600 institutions around the world.

(c) Defining mechanisms, clinical implications, and timing of mutation acquisition in hematologic neoplasms. Using newer forms of DNA sequencing, we have mapped out the ontogeny of mutations acquisition that leads to lymphoma. Building on my postdoctoral work in basic DNA double-strand break repair, we have published multiple papers defining the role of PARP enzymes in the formation of aberrant DNA rearrangements that drive lymphoid tumors. In addition, we are analyzing the genotypes of well-annotated lymphomas to develop improved prognostic algorithms that integrate genetic and clinical biomarkers.

### **Significant Supporting Activity: Clinical Expertise**

Given the close relationship between my laboratory research interests and its impact on clinical care, I have continued to maintain a presence on the clinical team, caring for patients undergoing blood and marrow transplantation. There, I utilize joint expertise in the fields of Medical Oncology and Infectious Diseases, both for clinical care and for clinical research. I have authored several manuscripts focused on infectious complications among stem cell transplant recipients, including Epstein Barr Virus, non-tuberculous mycobacteria, influenza, and Varicella Zoster Virus. One of my former trainees leads the effort at DFCI and BWH to perform clinical sequencing on all patients with lymphoma in a manner that will support clinical decision-making. Similar efforts from my laboratory have also led to the clinical testing of patients with B-cell acute lymphoblastic leukemia for alterations of the oncoprotein CRLF2 at DFCI, BWH and BCH, and mutations of the oncoproteins GNB1 and GNB2 in patients with any type of cancer.

### **Teaching and education**

I have served as an instructor in graduate school courses that focus on cancer and molecular biology. These have included Analysis of the Biological Literature (BBS 230), Critical Thinking and Research Proposal Writing (BBS 330) and Conduct of Science (Med-Sci 300QC). I also gave lectures to the HST Program students on lymphoma and plasma cell disorders. In my role as an attending physician at BWH, I educated interns, residents, fellows and HMS medical students on various aspects of clinical care and bone marrow transplantation. In my role as a Principal Investigator, I mentor undergraduate, medical and graduate students within the laboratory, as well as clinical and postdoctoral research fellows.

